<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77444</article-id><article-id pub-id-type="doi">10.7554/eLife.77444</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-268544"><name><surname>Kastenhuber</surname><given-names>Edward R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1872-212X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269427"><name><surname>Mercadante</surname><given-names>Marisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246709"><name><surname>Nilsson-Payant</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269426"><name><surname>Johnson</surname><given-names>Jared L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263402"><name><surname>Jaimes</surname><given-names>Javier A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6706-092X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79944"><name><surname>Muecksch</surname><given-names>Frauke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0132-5101</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200353"><name><surname>Weisblum</surname><given-names>Yiska</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9249-1745</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269428"><name><surname>Bram</surname><given-names>Yaron</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-272679"><name><surname>Chandar</surname><given-names>Vasuretha</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-190220"><name><surname>Whittaker</surname><given-names>Gary R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265120"><name><surname>tenOever</surname><given-names>Benjamin R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-268548"><name><surname>Schwartz</surname><given-names>Robert E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5417-5995</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-134226"><name><surname>Cantley</surname><given-names>Lewis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1298-7653</contrib-id><email>lcantley@med.cornell.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/005dvqh91</institution-id><institution>Department of Microbiology, New York University - Langone Health</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bnh6r87</institution-id><institution>Department of Microbiology and Immunology, Cornell University</institution></institution-wrap><addr-line><named-content content-type="city">Ithaca</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0420db125</institution-id><institution>Laboratory of Retrovirology, The Rockefeller University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>03</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e77444</elocation-id><history><date date-type="received" iso-8601-date="2022-02-08"><day>08</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-02-22"><day>22</day><month>02</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-04-01"><day>01</day><month>04</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.31.437960"/></event></pub-history><permissions><copyright-statement>© 2022, Kastenhuber et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kastenhuber et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77444-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-77444-figures-v2.pdf"/><abstract><p>Coagulopathy is a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. While certain host proteases, including TMPRSS2 and furin, are known to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry in the respiratory tract, other proteases may also contribute. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing infection at the stage of viral entry. Coagulation factors increased SARS-CoV-2 infection in human lung organoids. A drug-repurposing screen identified a subset of protease inhibitors that promiscuously inhibited spike cleavage by both transmembrane serine proteases and coagulation factors. The mechanism of the protease inhibitors nafamostat and camostat may extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage. Anticoagulation is critical in the management of COVID-19, and early intervention could provide collateral benefit by suppressing SARS-CoV-2 viral entry. We propose a model of positive feedback whereby infection-induced hypercoagulation exacerbates SARS-CoV-2 infectivity.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>coagulopathy</kwd><kwd>factor Xa</kwd><kwd>anticoagulants</kwd><kwd>nafamostat</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI35270</award-id><principal-award-recipient><name><surname>Whittaker</surname><given-names>Gary R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R35CA197588</award-id><principal-award-recipient><name><surname>Cantley</surname><given-names>Lewis</given-names></name><name><surname>Cantley</surname><given-names>Lewis</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010304</institution-id><institution>Pershing Square Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cantley</surname><given-names>Lewis</given-names></name><name><surname>Cantley</surname><given-names>Lewis</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Factor Xa and thrombin cleavage activate SARS-CoV-2 spike, widening the scope of host proteases involved in coronavirus entry and demonstrating the potential for dual anticoagulant/antiviral drugs.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>SARS-CoV-2 emerged into the human population in late 2019 and has evolved into a devastating global health crisis. Despite the recent success of vaccines (<xref ref-type="bibr" rid="bib3">Baden et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Polack et al., 2020</xref>), the limited world-wide vaccine distribution (<xref ref-type="bibr" rid="bib47">Kwok et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Nhamo et al., 2021</xref>; <xref ref-type="bibr" rid="bib75">So and Woo, 2020</xref>), the emergence of viral variants (<xref ref-type="bibr" rid="bib87">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib89">Weisblum et al., 2020</xref>), and the repeated SARS-like zoonotic outbreaks over the last 20 years (<xref ref-type="bibr" rid="bib15">Cheng et al., 2007</xref>; <xref ref-type="bibr" rid="bib23">Ge et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Menachery et al., 2015</xref>) underscore the urgent need to develop antivirals for coronavirus (<xref ref-type="bibr" rid="bib65">Pan et al., 2021</xref>).</p><p>In addition to attachment to specific receptors on target cells, coronaviruses require proteolytic processing of the spike protein by host cell proteases to facilitate membrane fusion and viral entry (<xref ref-type="bibr" rid="bib25">Glowacka et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Jaimes et al., 2020c</xref>; <xref ref-type="bibr" rid="bib86">Walls et al., 2020</xref>). In SARS-CoV-2, host cell proteases act on two sites residing at the S1/S2 subunit boundary and at the S2’ region proximal to the fusion peptide (<xref ref-type="bibr" rid="bib5">Belouzard et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib38">Jaimes et al., 2020b</xref>; <xref ref-type="bibr" rid="bib60">Millet and Whittaker, 2014</xref>). S1/S2 site cleavage opens up the spike trimer and exposes the S2’ site, which must be cleaved to allow for the release of the conserved fusion peptide (<xref ref-type="bibr" rid="bib7">Benton et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Madu et al., 2009</xref>). While the prevailing model suggests that furin cleaves the S1/S2 site and TMPRSS2 cleaves the S2’ site (<xref ref-type="bibr" rid="bib9">Bestle et al., 2020</xref>), it remains unclear to what extent other proteases may be involved (<xref ref-type="bibr" rid="bib32">Hoffmann et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Ou et al., 2020</xref>).</p><p>TMPRSS2 is an important host cell factor in proteolytic activation across multiple coronaviruses (<xref ref-type="bibr" rid="bib30">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib36">Jaimes et al., 2019</xref>). TMPRSS2 knockout or inhibition reduces infection in mouse models of SARS and MERS (<xref ref-type="bibr" rid="bib35">Iwata-Yoshikawa et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Zhou et al., 2015</xref>). More recently, TMPRSS2 has been highlighted as a drug target for SARS-CoV-2 (<xref ref-type="bibr" rid="bib30">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib31">Hoffmann et al., 2020b</xref>).</p><p>Furin activity is not essential to produce infectious particles (<xref ref-type="bibr" rid="bib82">Tang et al., 2021a</xref>) and furin is not necessary for cell fusion (<xref ref-type="bibr" rid="bib66">Papa et al., 2021</xref>), but deletion of the S1/S2 site attenuates SARS-CoV-2 in vivo (<xref ref-type="bibr" rid="bib40">Johnson et al., 2021</xref>). Proteolytic activation of envelope proteins presumably coordinates target cell engagement and envelope conformational changes leading to fusion. Furin cleavage during viral biogenesis, before release of viral particles, may render SARS-CoV-2 spike less stable in solution and reduce the likelihood to reach and interact with target cells (<xref ref-type="bibr" rid="bib2">Amanat et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Berger and Schaffitzel, 2020</xref>; <xref ref-type="bibr" rid="bib92">Wrobel et al., 2020</xref>). Although the S1/S2 site is often referred to as the ‘furin site’ (<xref ref-type="bibr" rid="bib40">Johnson et al., 2021</xref>), the full spectrum of proteases that catalyze biologically relevant activity in the lung remains incompletely defined.</p><p>Proteases also orchestrate the coagulation pathway, via a series of zymogens that are each activated by a chain reaction of proteolytic processing. Coagulopathy and thromboembolic events have emerged as a key component of COVID-19 pathogenesis (<xref ref-type="bibr" rid="bib55">McGonagle et al., 2020</xref>). Comorbidities associated with severe COVID-19 are also linked to dysregulated blood clotting (<xref ref-type="bibr" rid="bib97">Zhou et al., 2020</xref>). Patients with a history of stroke prior to infection have nearly twice the risk of in-hospital mortality (<xref ref-type="bibr" rid="bib70">Qin et al., 2020</xref>). Upon hospital admission, elevated D-dimer levels (an indicator of fibrinolysis and coagulopathy) and low platelet counts (an indicator of consumptive coagulopathy) are predictive biomarkers of severe disease and lethality in COVID-19 patients (<xref ref-type="bibr" rid="bib97">Zhou et al., 2020</xref>). Systemic activity of clotting factors V, VIII, and X are elevated in severe COVID-19 disease (<xref ref-type="bibr" rid="bib78">Stefely et al., 2020</xref>). While early phase disease is typically restricted to a local pulmonary hypercoagulable state, late-stage disease may be accompanied by systemic DIC, stroke, and cardio-embolism (<xref ref-type="bibr" rid="bib34">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Kipshidze et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">McGonagle et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Tsivgoulis et al., 2020</xref>). Ischemic stroke occurred in approximately 1% of hospitalized COVID-19 patients, and strikingly, a fraction of them experienced stroke even prior to onset of respiratory symptoms (<xref ref-type="bibr" rid="bib94">Yaghi et al., 2020</xref>).</p><p>In a drug-repurposing effort to target TMPRSS2, we observed that multiple direct-acting anticoagulants have anti-TMPRSS2 off-target effects. We subsequently investigated overlap in substrate specificity between TMPRSS2, factor Xa, and thrombin. Circulating proteases involved in blood clotting can cleave and activate SARS-CoV-2 spike, enhancing infection, specifically at the stage of viral entry. We propose that the serine protease inhibitor nafamostat may incorporate a combined mechanism in the treatment of COVID-19 through inhibition of TMPRSS2 and coagulation factors.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Serine protease inhibitors suppress SARS-CoV-2 entry via inhibition of TMPRSS2</title><p>We developed a fluorescence resonance energy transfer (FRET)-based protease enzymatic assay based on peptides containing either the S1/S2 or S2’ cleavage sites of SARS-CoV-2 spike (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Upon cleavage, the liberated 5-FAM emits fluorescent signal proportional to the quantity of product (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Camostat and nafamostat resulted in strong inhibition of TMPRSS2 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), as expected (<xref ref-type="bibr" rid="bib30">Hoffmann et al., 2020a</xref>; <xref ref-type="bibr" rid="bib31">Hoffmann et al., 2020b</xref>). We also identified that otamixaban and the active form of dabigatran (but not its prodrug dabigatran etexilate) inhibit TMPRSS2 enzymatic activity in vitro (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Anticoagulant serine protease inhibitors suppress SARS-CoV-2 entry via inhibition of TMPRSS2.</title><p>(<bold>A</bold>) Peptides derived from two known cleavage sites of SARS-CoV-2 spike were designed with C-terminal fluorophore 5-FAM and N-terminal fluorescence resonance energy transfer (FRET) quencher QXL-520. (<bold>B</bold>) FDA-approved and investigational serine protease inhibitors were screened by enzymatic assay to inhibit TMPRSS2 cleavage of SARS-CoV-2 S1/S2 peptide substrate. Relative change in fluorescence with respect to DMSO vehicle is shown. Colors indicate the described target of the drugs screened. All drugs screened at 10 µM final concentration. (<bold>C</bold>) Active form of dabigatran in enzymatic assay for TMPRSS2 inhibition. Relative fluorescence with respect to its corresponding 0.1 N HCl vehicle is shown. (<bold>D</bold>) Schematic of constructs used to generate SARS-CoV-2 spike-pseudotyped/HIV-1-based particles. (<bold>E</bold>) Calu3 cells were treated with 10 µM of the indicated drugs for 24 hr prior to infection with HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus. Media was changed at 24 hr post infection and pseudoviral entry was measured by nanoluciferase luminescent signal at 40 hr. (<bold>F</bold>) Calu3 cells treated with 10 µM of the indicated drugs were monitored for confluence by Incucyte for 40 hr. (<bold>G</bold>) Pseudoviral entry was measured by nanoluciferase luminescent signal in Calu3 cells treated various concentrations of the indicated drugs for 4 hr prior to infection with SARS-CoV-2 pseudovirus. (<bold>H</bold>) Caco2 cells were infected with lenti-Cas9-blast and U6-sgRNA-EFS-puro-P2A-tRFP and selected. Neutral controls targeting CD4 (not endogenously expressed) or PHGDH intron 1, two sgRNAs each targeting different regions of ACE2 and TMPRSS2 were included. Cells were subsequently infected with HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus. (<bold>I</bold>) Caco2 cells co-expressing Cas9 and sgRNAs targeting CD4 (not expressed) or TMPRSS2 were treated with 10 µM camostat, nafamostat, or DMSO vehicle. N = 3, *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data and summary statistics for enzymatic and pseudovirus assays.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-77444-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Optimization of fluorescence resonance energy transfer (FRET) enzymatic assay.</title><p>(<bold>A</bold>) TMPRSS2 enzymatic assay was performed in AB1 (20 mM Tris-HCl, pH 7.3, 100 mM NaCl, 1 mM EDTA, fresh 1 mM DTT) or AB2 (50 mM Tris-HCl, 150 mM NaCl, pH 8) using 10 µM of either S1/S2 or S2’ peptide substrate. (<bold>B</bold>) Titration of enzyme concentration was performed (0–1000 nM) with 10 µM S1/S2 substrate. Initial reaction velocity V<sub>0</sub> (rate of change in fluorescent signal) each enzyme concentration with 10 µM S1/S2 peptide substrate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Further characterization of HIV-1/SARS-CoV-2 pseudovirus.</title><p>A549 cells (which do not express ACE2), A549/ACE2 cells (ectopic ACE2 expression from a lentiviral vector), and Caco2 cells (which express endogenous ACE2 and TMPRSS2) infected with HIV-1<sub>NL</sub>-based particles pseudotyped with SARS-CoV-2 S or VSV G. N = 3, *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Further characterization of rVSV∆G/SARS-CoV-2 pseudovirus.</title><p>(<bold>A</bold>) Schematic of constructs used to generate SARS-CoV-2 spike-pseudotyped/VSV-based pseudovirus. (<bold>B</bold>) Nanoluciferase luminescent signal following addition of rVSV∆G pseudovirus complemented with VSV G, SARS-CoV-2 S, SARS-CoV S, or without complementation with any envelope protein to Calu3 cells. Each pseudovirus was titrated by adding the indicated volume of inoculum, supplemented with fresh media up to 200 µl/well in a 96-well plate. (<bold>C–F</bold>) Nanoluciferase luminescent signal following infection of (<bold>C</bold>) Caco2, (<bold>D</bold>) Calu3, (<bold>E</bold>) A549/ACE2, or (<bold>F</bold>) Vero cells with rVSV∆G/SARS-CoV-2 pseudovirus pretreated for 4 hr with 10 µM camostat, nafamostat, dabigatran, or otamixaban, compared with uninfected or infected/untreated cells. Expression status of ACE2 and TMPRSS2 for each cell line is indicated. N = 3. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Evidence of CRISPR knockout efficiency.</title><p>(<bold>A</bold>) Constructs used for CRISPR experiments. (<bold>B</bold>) Percentage of reads exhibiting wild type, frameshift, or in-frame indels at each locus for the indicated sgRNAs. (<bold>C–F</bold>) Distribution of reads with deletion or insertion by position within amplicon. (<bold>G–J</bold>) Distribution of the size of insertions and deletions in each amplicon. Two sgRNAs targeting ACE2 (g1 and g2) and two sgRNAs targeting TMPRSS2 (g1 and g2) were analyzed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig1-figsupp4-v2.tif"/></fig></fig-group><p>To explore these candidates in a cell-based functional assay of spike protein, SARS-CoV-2 S-pseudotyped HIV-1 particles were employed to infect human lung Calu3 cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref>). Consistent with the TMPRSS2 enzymatic assay, camostat, nafamaostat, otamixaban, and dabigatran etexilate suppressed pseudoviral entry, as indicated by nanoluciferase luminescent signal (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). No effects on relative cell growth were observed at the same timepoint in Calu3 (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) or A549 cells (data not shown), confirming that reduced luminescent signal was not due to cytotoxicity. A dose-response experiment with select protease inhibitors revealed a submicromolar IC50 for camostat and nafamostat and IC50s in the 10–20 µM range for otamixaban and dabigatran in Calu3 cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><p>Using A549 cells with or without ectopic ACE2 expression, we confirmed that HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus infection is dependent on ACE2, while infection with HIV-1<sub>NL</sub> pseudotyped instead with VSV G envelope protein is not ACE2 dependent (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Caco2 cells, which endogenously express ACE2 and TMPRSS2, show greater susceptibility to SARS-CoV-2 S-pseudotyped HIV-1<sub>NL</sub>, but equivalent susceptibility to VSV G-pseudotyped HIV-1<sub>NL</sub>, when compared to A549/ACE2 cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>To further validate these results in an alternative pseudovirus system, we used recombinant G protein-deficient vesicular stomatitis virus (rVSV∆G) pseudotyped with SARS-CoV-2-S (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>), yielding pseudovirus dependent on spike for cell entry (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). The antiviral effects of the four candidate protease inhibitors were confirmed in the VSV pseudovirus system in multiple cell lines, and response was associated with TMPRSS2 expression (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C-F</xref>).</p><p>We aimed to determine whether the effects of camostat and nafamostat are indeed TMPRSS2-dependent, or if other unidentified cellular proteases can compensate for TMPRSS2 suppression. To do so, we knocked out TMPRSS2 in ACE2<sup>+</sup> TMPRSS2<sup>+</sup> Caco2 cells and found that susceptibility to pseudovirus was significantly reduced, comparable to knockout of ACE2 (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Furthermore, both camostat and nafamostat reduce pseudovirus entry into control Caco2 cells harboring control sgRNA, but this trend was lost in cells with two independent TMPRSS2-targeting sgRNAs (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). These data indicate that, in the absence of exogenous proteases, TMPRSS2 is a critical host enzyme activating SARS-CoV-2 spike in TMPRSS2<sup>+</sup> cells and that TMPRSS2 is the primary target of camostat and nafamostat in these conditions.</p></sec><sec id="s2-2"><title>Coagulation factors directly cleave SARS-CoV-2 spike</title><p>Anticoagulants are highly represented among FDA-approved drugs that target proteases, and among the hits from the screen described above. The off-target effects of anticoagulants on TMPRSS2 imply that these small molecules can interact with the active sites of TMPRSS2 in a similar manner to coagulation factors. This led us to hypothesize that coagulation factors may interact with some of the same substrates as TMPRSS2, including SARS-CoV-2 spike.</p><p>To determine the properties of enzyme-substrate relationships, TMPRSS2, factor Xa, and thrombin cleavage of S1/S2 and S2’ peptides were determined over a range of 0–160 µM peptide substrate (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Surprisingly, factor Xa catalyzed S1/S2 cleavage more than an order of magnitude faster than TMPRSS2 (<xref ref-type="fig" rid="fig2">Figure 2A–B and D</xref>), although factor Xa showed lower affinity (higher K<sub>m</sub>) compared with TMPRSS2 to the S1/S2 peptide (<xref ref-type="fig" rid="fig2">Figure 2A–B and E</xref>). Thrombin has greater affinity (lower K<sub>m</sub>) than TMPRSS2 and factor Xa for the S1/S2 substrate (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and performs S1/S2 cleavage at a rate intermediate between TMPRSS2 and factor Xa (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Unlike factor Xa, thrombin cleaves the S2’ peptide with greater activity than TMPRSS2 (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Coagulation factors directly cleave SARS-CoV-2 spike.</title><p>Initial velocities for the cleavage of SARS-CoV-2 spike S1/S2 and S2’ peptide substrates by (<bold>A</bold>) TMPRSS2, (<bold>B</bold>) factor Xa, and (<bold>C</bold>) thrombin were measured over a range of 0–160 µM substrate. From initial velocity values, enzyme kinetic constants (<bold>D</bold>) turnover rate K<sub>cat</sub> (s<sup>–1</sup>), (<bold>E</bold>) affinity constant K<sub>m</sub>, and (<bold>F</bold>) specificity constant (K<sub>cat</sub>/K<sub>m</sub>) were obtained for the indicated enzymes with S1/S2 and S2’ peptides. (<bold>G–I</bold>) Heatmaps depict the initial velocity V<sub>0</sub> of cleavage of the indicated peptide substrates and concentrations by (<bold>G</bold>) TMPRSS2, (<bold>H</bold>) factor Xa, and (<bold>I</bold>) thrombin.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data and summary statistics for enzymatic assays.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-77444-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Fluorescence resonance energy transfer (FRET) enzymatic assay with modified peptide substrates.</title><p>(<bold>A–C</bold>) Initial reaction velocity with respect to enzyme concentration for peptide substrates of the SARS-CoV-2 spike S1/S2 site (S1S2), with P1 arginine substituted with alanine (S1S2-P1A), or with substitutions in the P3 and P4 position (RR &gt; SQ) with (<bold>A</bold>) TMPRSS2, (<bold>B</bold>) factor Xa, or (<bold>C</bold>) thrombin. (<bold>D</bold>) List of peptide substrates used in this study. (<bold>E</bold>) Initial reaction velocity of factor Xa cleavage of SARS-CoV-2 S1/S2 or thrombin-R271 peptide substrates in the presence of 0–100 µM phosphatidylcholine/phosphatidylserine (PC/PS) phospholipid vesicles. (<bold>F</bold>) Dilute Russell’s viper venom clotting time (dRVVT) assay of pooled normal human plasma, supplemented with 0–100 µM PC/PS phospholipid vesicles. N = 3, *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig2-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Kinetics of SARS-CoV-2 spike peptide substrate cleavage.</title><p>Kinetic constants obtained from initial velocity studies with varying concentrations of SARS-CoV-2 spike S1/S2 and S2’ peptide substrates. Each estimate is based on seven different concentrations of substrate in 1:2 serial dilution (0–160 µM).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Enzyme</th><th align="left" valign="bottom">Substrate</th><th align="left" valign="bottom">V<sub>max</sub> (µM/s)</th><th align="left" valign="bottom">K<sub>cat</sub> (s<sup>–1</sup>)</th><th align="left" valign="bottom">K<sub>m</sub> (µM)</th><th align="left" valign="bottom">K<sub>sp</sub> (s<sup>–1</sup> µM<sup>–1</sup>)</th></tr></thead><tbody><tr><td align="left" valign="bottom">TMPRSS2</td><td align="left" valign="bottom">S1/S2</td><td align="char" char="hyphen" valign="bottom">7.71E-04</td><td align="char" char="hyphen" valign="bottom">6.17E-03</td><td align="char" char="." valign="bottom">24.71</td><td align="char" char="hyphen" valign="bottom">2.50E-04</td></tr><tr><td align="left" valign="bottom">TMPRSS2</td><td align="left" valign="bottom">S2'</td><td align="char" char="hyphen" valign="bottom">4.60E-04</td><td align="char" char="hyphen" valign="bottom">3.68E-03</td><td align="char" char="." valign="bottom">60.94</td><td align="char" char="hyphen" valign="bottom">6.04E-05</td></tr><tr><td align="left" valign="bottom">Factor Xa</td><td align="left" valign="bottom">S1/S2</td><td align="char" char="hyphen" valign="bottom">2.24E-02</td><td align="char" char="hyphen" valign="bottom">1.79E-01</td><td align="char" char="." valign="bottom">40.35</td><td align="char" char="hyphen" valign="bottom">4.43E-03</td></tr><tr><td align="left" valign="bottom">Factor Xa</td><td align="left" valign="bottom">S2'</td><td align="char" char="hyphen" valign="bottom">3.04E-05</td><td align="char" char="hyphen" valign="bottom">2.43E-04</td><td align="char" char="." valign="bottom">2.711</td><td align="char" char="hyphen" valign="bottom">8.97E-05</td></tr><tr><td align="left" valign="bottom">Thrombin</td><td align="left" valign="bottom">S1/S2</td><td align="char" char="hyphen" valign="bottom">6.50E-03</td><td align="char" char="hyphen" valign="bottom">5.20E-02</td><td align="char" char="." valign="bottom">16.34</td><td align="char" char="hyphen" valign="bottom">3.18E-03</td></tr><tr><td align="left" valign="bottom">Thrombin</td><td align="left" valign="bottom">S2'</td><td align="char" char="hyphen" valign="bottom">7.34E-04</td><td align="char" char="hyphen" valign="bottom">5.87E-03</td><td align="char" char="." valign="bottom">13.98</td><td align="char" char="hyphen" valign="bottom">4.20E-04</td></tr></tbody></table></table-wrap><p>We next compared the ability of coagulation factors to cleave SARS-CoV-2 S to their ability to cleave their known substrates. During the physiological process of clotting, factor Xa cleaves prothrombin at R271, which ultimately becomes the activated form α-thrombin (<xref ref-type="bibr" rid="bib91">Wood et al., 2011</xref>). Thrombin, in turn, cleaves multiple sites of fibrinogen, including the beta chain (FGB) at R44, in a critical step toward aggregation and polymerization of high molecular weight fibrin clots. Fluorogenic peptides corresponding to THRB<sup>R271</sup> and FGB<sup>R44</sup> were synthesized and assayed with TMPRSS2, factor Xa, and thrombin. TMPRSS2 exhibited relatively broad activity to cleave this collection of substrates (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). As expected, factor Xa showed strong selectivity for THRB<sup>R271</sup> over FGB<sup>R44</sup>, while thrombin showed the opposite substrate preference (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>). Remarkably, factor Xa showed ~9-fold greater maximum initial reaction velocity (V<sub>max</sub>) in cleaving the spike S1/S2 peptide compared to cleaving a peptide corresponding to its known substrate, THRB<sup>R271</sup> (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). The V<sub>max</sub> for thrombin cleavage of the spike S1/S2 peptide was within ~4.5-fold of the V<sub>max</sub> for the benchmark FGB<sup>R44</sup> peptide (<xref ref-type="fig" rid="fig2">Figure 2I</xref>), indicating that thrombin might also cleave this site when activated during coagulation.</p><p>We next assessed the effect of substituting amino acids adjacent to the cleavage site of the S1/S2 peptide on proteolytic cleavage by these proteases. An arginine preceding the cleavage site (P1 position) is a common feature of substrates of many serine proteases. Substitution of the P1 arginine in the S1/S2 substrate with alanine (S1S2-P1A) resulted in a 4-fold reduction in TMPRSS2 cleavage and abolished nearly all cleavage by factor Xa and thrombin (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A-C</xref>). Substitutions in the P3 and P4 positions (S1S2-HPN) with features typical of a substrate of type II transmembrane serine proteases (TTSPs), a family which includes TMPRSS2 and hepsin (<xref ref-type="bibr" rid="bib19">Damalanka et al., 2019</xref>), did not change TMPRSS2 cleavage and greatly reduced factor Xa and thrombin cleavage (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A-C</xref>). Although the substrate specificity of TTSPs and coagulation factors are not universally similar, the cleavage sites of SARS-CoV-2 are specifically cleaved by TMPRSS2, factor Xa, and thrombin.</p><p>To consider whether the context of protease activity may influence substrate specificity, we repeated the enzymatic assay in the presence of phospholipids. The addition of phospholipid vesicles did not change factor Xa activity or substrate preference in this assay (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). To ensure the quality of our phospholipid vesicle preparation, we added 0–100 µM PC/PS to a dilute Russell’s viper venom time (dRVVT) clotting assay, where PC/PS drives a significant, concentration-dependent acceleration of clotting of normal pooled human plasma (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). In summary, the coagulation serine proteases factor Xa and thrombin exhibit proteolytic activity against SARS-CoV-2 spike peptide substrates.</p></sec><sec id="s2-3"><title>Factor Xa and thrombin facilitate SARS-CoV-2 spike-mediated entry</title><p>We next investigated whether coagulation factors could cleave trimeric spike in its native 3D conformation, and whether this activity potentiated spike function in viral entry into cells. To do so, we used replication-defective SARS-CoV-2 spike-pseudotyped VSV or HIV-1 virus (<xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref>). In the VSV pseudovirus system, addition of purified factor Xa or thrombin to the media significantly increased infection in Calu3 cells 16 hr post infection as determined by either quantification of NeonGreen (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) or nanoluciferase activity (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Factor Xa and thrombin facilitate SARS-CoV-2 spike-mediated entry.</title><p>(<bold>A</bold>) Calu3 cells were infected with rVSV∆G/SARS-CoV-2 pseudovirus with concomitant treatment with vehicle, 250 nM factor Xa, or 250 nM thrombin. Quantification of the ratio of green fluorescent area to total confluence (4 fields/replicate well, 4 wells/condition). (<bold>B</bold>) Nanoluciferase luminescent signal was measured following infection with rVSV∆G/SARS-CoV-2 pseudovirus and the addition of either vehicle, factor Xa, or thrombin. The effect of factor Xa on rVSV∆G complemented with either (<bold>C</bold>) SARS-CoV spike or (<bold>D</bold>) VSV-G was measured by luminescent signal. Luminescent signal was measured following HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus infection and concomitant treatment with 125–250 nM factor Xa in (<bold>E</bold>) Calu3 cells, (<bold>F</bold>) A549/ACE2, and (<bold>G</bold>) Vero cells following transduction with lentiviral vectors to express GFP or TMPRSS2. Following selection, cells were infected with HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus and concomitantly treated with 125–250 nM factor Xa. Subsequently, nanoluciferase luminescent signal was determined and plotted relative to vehicle-treated control. *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data and summary statistics for pseudovirus assays with exogenous proteases.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-77444-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Further characterization of coagulation factor-induced SARS-CoV-2 pseudovirus infection.</title><p>(<bold>A</bold>) Representative merged brightfield and green fluorescence images of Calu3 cells without infection or following rVSV∆G/SARS-CoV-2 pseudovirus infection and concomitant treatment with vehicle, 250 nM factor Xa, or 250 nM thrombin (corresponding to <xref ref-type="fig" rid="fig3">Figure 3A</xref>). Scale bars represent 300 µm. (<bold>B–E</bold>) HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus with addition of purified protease or vehicle. Nanoluciferase luminescent signal relative to vehicle-treated control was measured following infection in (<bold>B</bold>) A549/ACE2 and (<bold>C</bold>) Vero cells. Cell abundance following protease treatment, relative to vehicle control was determined for (<bold>D</bold>) A549/ACE2 and (<bold>E</bold>) Vero cells. N = 3, *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Assessing relevant protease levels with ex vivo clotting assays.</title><p>(<bold>A</bold>) Factor X activity was determined by dilute Russell’s viper venom clotting time (dRVVT). Pooled normal plasma or FX-deficient plasma with the addition of the indicated concentration of active purified factor Xa were assayed. (<bold>B</bold>) Prothrombin activity was determined by prothrombin time (PT) via activation with thromboplastin. Pooled normal plasma or prothrombin-deficient plasma with the addition of the indicated concentration of active purified thrombin were assayed. N = 3. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig3-figsupp2-v2.tif"/></fig></fig-group><p>While factor X and prothrombin levels are variable between individuals in healthy populations (<xref ref-type="bibr" rid="bib10">Brummel-Ziedins et al., 2012</xref>), the concentration of proteases used in the pseudovirus assay (125–250 nM) are comparable to reference ranges of factor X (<xref ref-type="bibr" rid="bib10">Brummel-Ziedins et al., 2012</xref>; <xref ref-type="bibr" rid="bib84">Tormoen et al., 2013</xref>; <xref ref-type="bibr" rid="bib90">Williams and Marks, 1994</xref>) and prothrombin (<xref ref-type="bibr" rid="bib4">Baugh et al., 1998</xref>; <xref ref-type="bibr" rid="bib10">Brummel-Ziedins et al., 2012</xref>; <xref ref-type="bibr" rid="bib84">Tormoen et al., 2013</xref>). Similar concentrations of active purified proteases were required to normalize in vitro clotting times, where purified factor Xa was used to correct dRVVT of factor X-deficient human plasma (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>) and purified thrombin was used to correct the prothrombin time of prothrombin-deficient human plasma (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>).</p><p>SARS-CoV-2 contains a notable insertion of basic residues at the S1/S2 boundary, distinguishing its sequence from many related betacoronaviruses (<xref ref-type="bibr" rid="bib37">Jaimes et al., 2020a</xref>). Entry of rVSV∆G was increased when complemented with spike protein from SARS-CoV of the 2002 outbreak (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), but not when complemented instead with VSV G (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This indicates that factor Xa spike cleavage could be relevant across multiple coronaviruses, but is not generally associated with VSV entry.</p><p>We further validated that factor Xa activated spike-mediated entry the HIV-1-based pseudovirus system (<xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref>). Consistent with the results above, addition of purified factor Xa to the media at the time of infection enhanced entry of HIV-1-based SARS-CoV-2 pseudovirus in Calu3 cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Thrombin did not appear to enhance spike-mediated entry by HIV-1/SARS-CoV-2 pseudovirus, unlike rVSV∆G/SARS-CoV-2 pseudovirus (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B-E</xref>).</p><p>We investigated the functional interplay of TMPRSS2 expression and the effect of exogenous activated coagulation factors. TMPRSS2 is expressed in Calu3 cells and contributes to coronavirus entry (<xref ref-type="bibr" rid="bib30">Hoffmann et al., 2020a</xref>), whereas A549/ACE2 and Vero cells lack endogenous TMPRSS2 expression. Factor Xa induced a significant dose-dependent effect on pseudovirus entry in both Calu3 and A549/ACE2 (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>). Furthermore, an isogenic pair of Vero cells was generated by expressing TMPRSS2 or GFP control. Pseudovirus infection of both Vero<sup>GFP</sup> and Vero<sup>TMPRSS2</sup> cells were significantly increased by factor Xa, indicating that factor Xa enhancement of infection is not dependent on TMPRSS2 (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). This is consistent with the model that FXa cuts the S1/S2 site and TMPRSS2 has functionally important activity at the S2’ site.</p></sec><sec id="s2-4"><title>Nafamostat broadly inhibits cleavage of spike peptides by both transmembrane serine proteases and coagulation factors</title><p>Given that multiple proteases could contribute to SARS-CoV-2 spike cleavage activation, a drug that could inhibit both transmembrane serine proteases and coagulation factors would be potentially valuable as a dual action anticoagulant/antiviral in COVID-19. Accordingly, we next explored the candidate set of inhibitors for cross-reactivity against a broader set of proteases that could facilitate viral entry. Like TMPRSS2, human airway trypsin-like protease (HAT), encoded by <italic>TMPRSS11D</italic>, is a member of the TTSP family of proteases and could activate SARS-CoV-2 S (<xref ref-type="bibr" rid="bib32">Hoffmann et al., 2021</xref>). HAT exhibited sensitivity to camostat and nafamostat, similar to TMPRSS2 (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Compared to TMPRSS2, HAT was more sensitive to dabigatran and less sensitive to otamixaban (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Factor Xa activity against the S1/S2 peptide was most sensitive to otamixaban and moderately sensitive to nafamostat and dabigatran (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Thrombin activity was sensitive to camostat, nafamostat, and dabigatran, and moderately sensitive to otamixaban (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Nafamostat broadly inhibits cleavage of spike peptides by both coagulation factors and transmembrane serine proteases.</title><p>Initial velocities for the cleavage of 10 µM SARS-CoV-2 spike S1/S2 (top) and S2’ (bottom) peptide substrates by (<bold>A</bold>) TMPRSS2, (<bold>B</bold>) TMPRSS11D/human airway trypsin-like protease (<bold>C</bold>) factor Xa, and (<bold>D</bold>) thrombin were measured in the presence of DMSO vehicle, or 10 µM camostat, nafamostat, otamixaban, or dabigatran. The relative activity of (<bold>E</bold>) factor Xa and (<bold>F</bold>) thrombin were determined over a range of 0–10 µM of the indicated drugs. Calu3 cells were treated with a range of concentrations of nafamostat with or without addition of 250 nM exogenous factor Xa and infected with (<bold>G</bold>) rVSV∆G/SARS-CoV-2 pseudovirus or (<bold>H</bold>) HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus and infectivity was measured by luminescence. N = 3, data represented as mean ± SEM.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data and summary statistics for enzymatic assays to determine the effects of protease inhibitors on host proteases.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-77444-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Activity of candidate inhibitors against other proteases.</title><p>Initial reaction velocity V<sub>0</sub> of furin, TMPRSS4, or neutrophil elastase cleavage of (<bold>A</bold>) S1/S2 peptide substrate or (<bold>B</bold>) S2’ peptide substrate, treated with DMSO vehicle, camostat, nafamostat, otamixaban, or dabigatran. 10 µM substrate and 10 µM inhibitor were used.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Apixaban rescues effect of factor Xa, related to <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>Calu3 cells were infected with rVSV∆G/SARS-CoV-2 pseudovirus with addition of protease buffer (left) or factor Xa (right). Cells were treated at the time of infection with DMSO vehicle (black), 1 or 10 µM nafamostat (red), or 1 or 10 µM apixaban (orange). N = 6, *p &lt; 0.05, two-tailed t-test. Data represented as mean ± SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig4-figsupp2-v2.tif"/></fig></fig-group><p>We performed a dose-response curve of the panel of inhibitors on factor Xa and thrombin S1/S2 cleavage. Otamixaban, a designed factor Xa inhibitor, demonstrated an IC50 at the nanomolar level to factor Xa, while nafamostat and dabigatran demonstrated IC50s in the micromolar range (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Camostat did not potently inhibit factor Xa spike cleavage. Dabigatran, a designed thrombin inhibitor, as well as nafamostat and camostat demonstrated a submicromolar IC50 for thrombin-dependent spike cleavage (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Otamixaban inhibited thrombin spike cleavage in the micromolar range.</p><p>Furin showed high activity against the S1/S2 peptide, but not against the S2’ peptide, and was not sensitive to any of the candidate inhibitors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-B</xref>). While it has been suggested that TMPRSS4 or neutrophil elastase may also cleave SARS-CoV-2 spike, we detected minimal activity against either S1/S2 or S2’ peptide substrates in our enzymatic assay (&lt;1% of furin cleavage of S1/S2) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-B</xref>).</p><p>In the pseudovirus assay, nafamostat effectively suppresses SARS-CoV-2 S-mediated entry with or without the addition of exogenous factor Xa, using either the VSV-based (<xref ref-type="fig" rid="fig4">Figure 4G</xref>) or HIV-1-based (<xref ref-type="fig" rid="fig4">Figure 4H</xref>) SARS-CoV-2 pseudovirus. To clarify the pleiotropic nature of nafamostat, which inhibits TMPRSS2 and factor Xa, we compared the effect of apixaban, which inhibits factor Xa but not TMPRSS2. Apixaban rescued the effect of exogenous FXa back to the baseline level of infection, but did not affect pseudovirus infection in the absence of exogenous protease (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Direct oral anticoagulants (DOACs) have the potential to block clotting factor-mediated enhancement of viral entry, but TMPRSS2-mediated cleavage activation would remain unaffected by treatment with DOACs in common usage in North America and Europe. Taken together, nafamostat appears to be a versatile inhibitor of spike activation by a variety of TTSPs and coagulation factors. The multitarget mechanism of nafamostat distinguishes its potential as an antiviral/anticoagulant from currently FDA-approved DOACs.</p></sec><sec id="s2-5"><title>Factor Xa and thrombin increase SARS-CoV-2 infection in lung organoids</title><p>To explore the effect of coagulation factors in a more physiologically relevant setting, we exposed human pluripotent stem cell-derived lung organoids (hPSC-LOs) to SARS-CoV-2 infection under BSL-3 conditions with or without addition of exogenous protease. Stepwise, directed differentiation of human pluripotent stem cells generates lung organoids that form three-dimensional cellular structures and recapitulate functional and molecular characteristics of the lung (<xref ref-type="bibr" rid="bib13">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Han et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Huang et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Mou et al., 2012</xref>). hPSC-LOs express alveolar type II cell markers and were previously shown to be permissive to SARS-CoV-2 infection and replication (<xref ref-type="bibr" rid="bib28">Han et al., 2021</xref>).</p><p>Mature lung organoids were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 (<xref ref-type="fig" rid="fig5">Figure 5A–B</xref>) or 0.01 (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>) and viral replication was measured by quantitative real-time PCR (qRT-PCR) for SARS-CoV-2 nucleocapsid (<italic>N</italic>) (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>) and SARS-CoV-2 envelope (<italic>E</italic>) (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>). The addition of either factor Xa or thrombin increased the levels of viral RNA following infection (<xref ref-type="fig" rid="fig5">Figure 5A–D</xref>). This effect was accentuated at 48 hr post infection with respect to 24 hr post infection, and with lower initiating MOI. Factor Xa and thrombin increase SARS-CoV-2 infection in the context of multicycle viral replication in human lung organoids.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Factor Xa and thrombin increase SARS-CoV-2 infection in lung organoids.</title><p>Human pluripotent stem cell (hPSC)-derived lung organoids were infected with SARS-CoV-2. Upon infection, organoids were treated with 170 nM of purified factor Xa or thrombin. (<bold>A</bold>) Relative level of SARS-CoV-2-N RNA following infection at multiplicity of infection (MOI) = 0.1. (<bold>B</bold>) Relative level of SARS-CoV-2-E RNA following infection at MOI = 0.1. (<bold>C</bold>) Relative level of SARS-CoV-2-N RNA following infection at MOI = 0.01. (<bold>D</bold>) Relative level of SARS-CoV-2-E RNA following infection at MOI = 0.01. N = 16, *p = 0.0144, ***p &lt; 0.0001, two-tailed t-test. Data represented as mean ± SEM.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data and summary statistics for infection assays with exogenous proteases.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-77444-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-77444-fig5-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Coagulation factors cleave the SARS-CoV-2 spike protein</title><p>Using a FRET-based enzymatic assay, two platforms of pseudovirus assays, and SARS-CoV-2 infection experiments in lung organoids, we demonstrate that coagulation proteases factor Xa and thrombin cleave SARS-CoV-2 spike protein. Coagulation-induced cleavage enhances spike activation and increases viral entry into target cells, potentially instigating a positive feedback loop with infection-induced coagulation. Nafamostat, among currently available drugs, is best suited as a multi-purpose inhibitor against spike cleavage by TTSPs and coagulation factors. These data have numerous implications at the intersection of virology and coagulation.</p></sec><sec id="s3-2"><title>Viral envelope protein activation by non-target cell proteases</title><p>Hijacking of host transmembrane, endosomal, and ER proteases to activate viral envelope proteins has been described in influenza A, human metapneumovirus, HIV, and Sendai virus (<xref ref-type="bibr" rid="bib44">Kido et al., 1996</xref>; <xref ref-type="bibr" rid="bib80">Straus et al., 2020</xref>). In the present study, we find an instance where the virus can be primed not by proteases expressed by the target cell, but by host organism proteases derived from the microenvironment of the target cell. Prior studies have described cleavage activation of SARS-CoV by elastase and plasmin, illustrating that microenvironmental host proteases can indeed play an important role in coronavirus spike priming (<xref ref-type="bibr" rid="bib6">Belouzard et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Kam et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Matsuyama et al., 2005</xref>). Generally, the scope by which circulating proteases, such as coagulation factors, or proteases expressed by immune cells interact with viral envelope proteins during infection has not been comprehensively explored.</p><p>Relatively few studies have examined the interaction of factor Xa or thrombin and viral proteins, and each relies on target cells as the source of coagulation factors. Our results are consistent with a prior study that concluded that factor Xa cleaves and activates SARS-CoV spike (<xref ref-type="bibr" rid="bib21">Du et al., 2007</xref>). Traditionally, influenza vaccines rely on viral propagation in chicken eggs, where hemagglutinin cleavability by factor Xa is a determinant of the efficiency of strain-specific propagation of influenza A virus in ovo (<xref ref-type="bibr" rid="bib26">Gotoh et al., 1990</xref>; <xref ref-type="bibr" rid="bib79">Straus and Whittaker, 2017</xref>). Hepatitis E virus ORF1 polyprotein is processed intracellularly by thrombin and factor Xa in the cytoplasm of hepatocytes, which are the primary cell type responsible for generating and secreting coagulation factors (<xref ref-type="bibr" rid="bib42">Kanade et al., 2018</xref>).</p><p>Activation of coagulation has the potential to exacerbate SARS-CoV-2 infectivity in both TMPRSS2<sup>+</sup> and TMPRSS2<sup>-</sup> host cells. Reliance on extracellular proteolytic activity could expand the field of susceptible cell types and regions of the airway. Extrapulmonary infection has been described, particularly in small intestinal enterocytes (<xref ref-type="bibr" rid="bib93">Xiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib95">Zang et al., 2020</xref>) and, in some cases, the central nervous system (<xref ref-type="bibr" rid="bib76">Song et al., 2021</xref>). It warrants investigation whether hypercoagulation is linked to extrapulmonary infection.</p></sec><sec id="s3-3"><title>Evolutionary perspective on viral-host interaction</title><p>Proteolytic cleavage of the spike forms a barrier to zoonotic crossover independent of receptor binding (<xref ref-type="bibr" rid="bib57">Menachery et al., 2020</xref>). Hemostasis is of central importance in mammals and represents a major vulnerability of mammals to predators and pathogens, either through hyperactivation of coagulation or uncontrolled bleeding. The dysregulation of hemostasis is a convergent mechanism of toxins of snakes, bees, and bats (<xref ref-type="bibr" rid="bib50">Ma et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Markland and Swenson, 2013</xref>; <xref ref-type="bibr" rid="bib69">Prado et al., 2010</xref>) and a driver of virulence in Ebola and dengue virus infection (<xref ref-type="bibr" rid="bib24">Geisbert et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Rathore et al., 2019</xref>). Acute lung injury from viral cytopathic effects, the induction of a COVID-19-associated cytokine storm, complement activation, and anti-phospholipid autoantibodies have all been suggested to instigate the coagulation cascade (<xref ref-type="bibr" rid="bib58">Merrill et al., 2020</xref>; <xref ref-type="bibr" rid="bib98">Zuo et al., 2020</xref>). Furthermore, one model posits that COVID-19 coagulopathy is platelet-driven and an Arg-Gly-Asp (RGD) motif on SARS-CoV-2 spike directly interacts with GPIIb/GPIIIa integrins on the surface of platelets (<xref ref-type="bibr" rid="bib17">Cox, 2021</xref>), consistent with in silico predictions of integrin binding (<xref ref-type="bibr" rid="bib59">Mészáros et al., 2021</xref>). Perhaps, SARS-CoV-2 has undergone selection to exploit an environment locally enriched in coagulation proteases for enhanced entry. As infection spreads, more clotting is induced, instigating a positive feedback loop to promote entry into additional host cells.</p></sec><sec id="s3-4"><title>Clinical relevance of potential antiviral activity of anticoagulants</title><p>Effective anticoagulation is a critical area of investigation to improve outcomes in coronavirus infection. Vitamin K antagonists, including heparin, are commonly used for preventing venous thromboembolism in COVID-19, although no strong evidence yet supports any specific anticoagulant (<xref ref-type="bibr" rid="bib18">Cuker et al., 2021</xref>). Three large randomized clinical trials to determine the benefit of therapeutic intensity vs. prophylactic intensity heparin in critically ill COVID-19 patients were suspended at interim analysis for futility (NCT02735707, NCT04505774, and NCT04372589). There has been interest in the use of direct-acting oral anticoagulants (DOACs) to manage COVID-19-related coagulopathy, but optimal protocols for managing coagulopathy in COVID-19 patients have not yet been developed (<xref ref-type="bibr" rid="bib11">Capell et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Lopes et al., 2021</xref>). The most prominent risk of anticoagulants is bleeding, and notably DOACs, as well as nafamostat, have a reduced risk of intracranial hemorrhage and other bleeding events compared to vitamin K antagonists (<xref ref-type="bibr" rid="bib14">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Hellenbart et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Makino et al., 2016</xref>).</p><p>In our studies, anticoagulant serine protease inhibitors, otamixaban and dabigatran, exhibited off-target activity against TMPRSS2 and other TTSPs, but likely require concentrations higher than those safely reached in vivo (<xref ref-type="bibr" rid="bib64">Paccaly et al., 2006</xref>; <xref ref-type="bibr" rid="bib77">Stangier and Clemens, 2009</xref>). On the other hand, our data suggest that nafamostat and camostat may offer three distinct therapeutic mechanisms against SARS-CoV-2 infection; these compounds have the potential to block spike cleavage mediated by TMPRSS2 and other TTSPs, to block spike cleavage by coagulation factors, and to serve as an anticoagulant. It is also plausible that nafamostat, like related protease inhibitor pentamidine, could also interfere with platelet GPIIb/IIIa, platelet aggregation, and thrombus formation (<xref ref-type="bibr" rid="bib17">Cox, 2021</xref>; <xref ref-type="bibr" rid="bib16">Cox et al., 1996</xref>). Nafamostat (<xref ref-type="bibr" rid="bib22">Fujii and Hitomi, 1981</xref>; <xref ref-type="bibr" rid="bib43">Keck et al., 2001</xref>; <xref ref-type="bibr" rid="bib81">Takeda et al., 1996</xref>) and Camostat (<xref ref-type="bibr" rid="bib71">Ramsey et al., 2019</xref>) have been in clinical use in Asia for many years for the treatment of pancreatitis. Nafamostat has also been used as an anticoagulant during hemodialysis (<xref ref-type="bibr" rid="bib1">Akizawa et al., 1993</xref>) and extracorporeal membrane oxygenation (<xref ref-type="bibr" rid="bib67">Park et al., 2015</xref>), and to manage disseminated intravascular coagulopathy (<xref ref-type="bibr" rid="bib46">Kobayashi et al., 2001</xref>). As of this writing, there have been eight clinical trials initiated (reported on <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</ext-link>) to investigate the use of nafamostat in COVID-19, while 24 active clinical trials of camostat for COVID-19 were identified.</p><p>Inhibition of coagulation factor-induced spike cleavage may contribute to the molecular mechanism of these agents, if treatment is given sufficiently early. Many COVID-19-associated complications leading to hospitalization occur as immune hyperactivation waxes and peak viral titer wanes (<xref ref-type="bibr" rid="bib27">Griffin et al., 2021</xref>). To take advantage of the potential antiviral effect of anticoagulants, early intervention in an outpatient setting may be beneficial.</p></sec><sec id="s3-5"><title>Limitations</title><p>The experiments of this study, like prior studies using similar techniques, have some limitations. Protease enzymatic assays on peptide substrates allow for detailed biochemical characterization of a specific site, but peptide substrates may not have the equivalent three-dimensional conformation or post-translational modifications of the full-length protein produced in appropriate cells. For instance, SARS-CoV-2 S is extensively glycosylated (<xref ref-type="bibr" rid="bib88">Watanabe et al., 2020</xref>). The possibility of additional spike cleavage sites and potential pro- and anti-viral consequence of proteases acting on cell surface proteins including ACE2 cannot be excluded. The amount, density, and accessibility of spike protein could be different between pseudovirus assays and wild type (WT) SARS-CoV-2 infection. However, antibody neutralization is highly correlated between authentic virus and corresponding pseudotyped viruses, suggesting similar conformation (<xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref>). We confirmed our results using WT SARS-CoV-2 infection, which alone does not easily allow for precise definition of which stage of the viral replication cycle is being affected, but pseudovirus assays confirm a cell-entry mechanism. We have attempted to mitigate the risk of artifact by using multiple orthogonal platforms.</p></sec><sec id="s3-6"><title>Conclusion</title><p>Collectively, our data provide rationale for the investigation of early intervention with judiciously selected anticoagulant treatment, which may have collateral benefit in limiting progressive spread of SARS-CoV-2 infection throughout the lung in infected individuals. Preparedness to mitigate future coronavirus outbreaks is critical to pursue through the understanding of coronavirus-host interactions.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Camostat</td><td align="left" valign="bottom">Selleck</td><td align="left" valign="bottom">Cat# S2874</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nafamostat</td><td align="left" valign="bottom">Selleck</td><td align="left" valign="bottom">Cat# S1386</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Apixaban</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-50667</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Betrixaban</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10268</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bivalirudin (TFA)</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-15664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Boceprevir</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10237</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dabigatran etexilate</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10274</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Edoxaban</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10264</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Otamixaban</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-70035</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rivaroxaban</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-50903</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Simeprevir</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10241</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sivelestat</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-17443</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Telaprevir</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10235</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dabigatran</td><td align="left" valign="bottom">Medchem Express</td><td align="left" valign="bottom">Cat# HY-10163</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Thrombin</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat# 605195</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Factor Xa</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat# 69036</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TMPRSS2</td><td align="left" valign="bottom">LSBio</td><td align="left" valign="bottom">Cat# LS-G57269</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TMPRSS4</td><td align="left" valign="bottom">Aviva System Biology</td><td align="left" valign="bottom">Cat# OPCA0240</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Furin</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 1503SE010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Neutrophil elastase</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 9167SE020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">S1/S2</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-PRRARSVASQ-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">S2’</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-KPSKRSFIED-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">THRB-R271</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-AIEGRTATSE-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGB-R44</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-FFSARGHRPL-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">S1/S2-P1A</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-PRRAASVASQ-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">S1/S2-HPN</td><td align="left" valign="bottom">Anaspec</td><td align="left" valign="bottom"/><td align="left" valign="bottom">QXL520-PSQARSVASQ-K(5-FAM)-NH2</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatidylcholine</td><td align="left" valign="bottom">Avanti Polar Lipids</td><td align="left" valign="bottom">Cat# 850375C</td><td align="left" valign="bottom">1,2-Dioleoyl-<italic>sn</italic>-glycero-3-phosphocholine</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">phosphatidylserine</td><td align="left" valign="bottom">Avanti Polar Lipids</td><td align="left" valign="bottom">Cat# 840035C</td><td align="left" valign="bottom">1,2-Dioleoyl-<italic>sn</italic>-glycero-3-phospho-L-serine</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Calu3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# HTB-55; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0609">CVCL_0609</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">A549</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-185; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0023">CVCL_0023</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Caco2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# HTB-37; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0025">CVCL_0025</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Chlorocebus sabaeus</italic>)</td><td align="left" valign="bottom">Vero</td><td align="left" valign="bottom">Laboratory of Benjamin tenOever</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0059">CVCL_0059</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-3216; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGPN</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGPN-ACE2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGPN-TMPRSS2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Lenti-Cas9-blast</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat# 52962</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">ipUSEPR</td><td align="left" valign="bottom">Francisco Sanchez-Rivera &amp; Scott Lowe</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CMV-SARS-CoV-2-S</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CCNanoLuc/GFP</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HIV-1NL GagPol</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBuilder master mix</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# E2621</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">XtremeGene9</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat# 6365787001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polybrene</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# SC-134220</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lenti-X</td><td align="left" valign="bottom">Takara Bio</td><td align="left" valign="bottom">Cat# 631232</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">G418</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# # G8168</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Blasticidin</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Cat# ANT-BL-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A1113803</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cell Lysis Buffer</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# E1531</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NanoGlo Luciferase Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# N1130</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Normal human plasma</td><td align="left" valign="bottom">Pacific Hemostasis</td><td align="left" valign="bottom">Cat# 95059–698</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Factor X-deficient plasma</td><td align="left" valign="bottom">Haematologic Technologies</td><td align="left" valign="bottom">Cat# FX-ID</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Prothrombin-deficient plasma</td><td align="left" valign="bottom">Haematologic Technologies</td><td align="left" valign="bottom">Cat# FII-ID</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Vipera russelli</italic>)</td><td align="left" valign="bottom">Russell’s Viper Venom</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# V2501</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Indiana vesiculovirus</italic>)</td><td align="left" valign="bottom">rVSVdG/NG-NanoLuc</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (SARS-CoV-2)</td><td align="left" valign="bottom">SARS-CoV-2, isolate USA-WA1/2020</td><td align="left" valign="bottom">BEI Resources, NIAID, NIH</td><td align="left" valign="bottom">Cat# NR-52281</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: CD4</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">GGTGCAATGTAGGAGTCCAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: PHGDH intron1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">GGGCGAGAGAGAGAAAATTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: ACE2 g1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">CACCGCAAAGGCGAGAGATAGTTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: ACE2 g2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">CACCGACATCTTCATGCCTATGTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: TMPRSS2 g1</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">CACCGCTGGAACGAGAACTACGGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sgRNA: TMPRSS2 g2</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">sgRNA</td><td align="left" valign="bottom">CACCGGGGACGGGTAGTACTGAGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: CD4-Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GATAATGGAGAGATGTTGTTGGTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: CD4- Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATGTCCAGGTGCCACTATCCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: PHGDH intron 1 – Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AAAGCAGAACCTTAGCAAAGAGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: PHGDH intron 1 – Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAACTAATTGATACGGGGTGCAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: ACE2-g1- Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCCTACTTTTTGTCGTTATTAGCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: ACE2-g1- Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGTGATCCACAGCTAATGTATTGTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: ACE2-g2- Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCAAAATGCGATTTCTACAATGTTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: ACE2-g2- Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGGGCTTTTCAGATTAAACCATTAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: TMPRSS2-g1-Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACAAATTCCACCTGCTGGTTATAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: TMPRSS2-g1- Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTTCATCCTTCAGGTGTACTCATC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: TMPRSS2-g2- Forward</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAGGAAATAAACACAAAGAGAATCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer: TMPRSS2-g2-Reverse</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACTATGAAAACCATGGATACCAACC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS-CoV-2-N-F</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TAATCAGACAAGGAACTGATTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS-CoV-2-N-R</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CGAAGGTGTGACTTCCATG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS-CoV-2-E-F</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ACAGGTACGTTAATAGTTAATAGCGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SARS-CoV-2-E-R</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATATTGCAGCAGTACGCACACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human 18S-F</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCCCTGTAATTGGAATGAGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Human 18S-R</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCAAGATCCAACTACGAGCTT</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Enzymatic assay</title><p>Thrombin (605195, human, activated by factor Xa, factor Va, and phospholipid) and factor Xa (69036, bovine, activated by Russell’s Viper Venom) were obtained from Millipore Sigma. Recombinant TMPRSS2, purified from yeast, was obtained from LSBio (LS-G57269). TMPRSS4 was obtained from Aviva System Biology (OPCA0240), furin was obtained from Thermo Fisher Scientific (1503SE010), neutrophil elastase was obtained from Thermo Fisher Scientific (9167SE020). FRET peptides were obtained from Anaspec, and a peptide sequences are listed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>. Protease assay buffer was composed of 50 mM Tris-HCl, 150 mM NaCl, pH 8. Enzyme dilution/storage buffer was 20 mM Tris-HCl, 500 mM NaCl, 2 mM CaCl<sub>2</sub>, 50% glycerol, pH 8. Peptides were reconstituted and diluted in DMSO. Enzyme kinetics were assayed in black 96-well plates with clear bottom and measured using a BMG Labtech FLUOstar Omega plate reader, reading fluorescence (excitation 485 nm, emission 520 nm) every minute for 20 cycles, followed by every 5 min for an additional eight cycles. A standard curve of 5-FAM from 0 to 10 µM (1:2 serial dilutions) was used to convert RFU to µM of cleaved FRET peptide product. Calculation of enzyme constants was performed with GraphPad Prism software (version 9.0). Camostat and nafamostat were obtained from Selleck Chemicals and all other inhibitors were obtained from MedChem Express.</p></sec><sec id="s4-2"><title>Phospholipid vesicles</title><p>Phosphatidylcholine (1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphocholine, Avanti Polar Lipids #850375C) and phosphatidylserine (1,2-dioleoyl-<italic>sn</italic>-glycero-3-phospho-L-serine, Avanti Polar Lipids #840035C) were mixed in a 3:1 w/w ratio in chloroform solvent in a screw top vial and the chloroform solvent was evaporated under a nitrogen stream. Unilamellar vesicles were isolated by extrusion using 0.1 µm pore filters and diluted in buffer AB2 (50 mM Tris-HCl, 150 mM NaCl, pH 8).</p></sec><sec id="s4-3"><title>Cell culture</title><p>Calu3, A549, Caco2, and Vero cells were tested for mycoplasma (Lonza MycoAlert detection kit) and human cell line identity was authenticated by ATCC. A549 and Vero cells were grown in DMEM, supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. Calu3 and Caco2 cells were grown in MEM, supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 1% MEM NEAA, and 1 mM sodium pyruvate.</p></sec><sec id="s4-4"><title>Plasmids and lentivirus infection</title><p>Overexpression constructs pEGPN-GFP, pEGPN-ACE2, and pEGPN-TMPRSS2 were constructed by Gibson cloning using NEBuilder master mix (New England Biolabs, E2621) with overlapping PCR generated inserts for promoter EF1α, the gene of interest, promoter PGK, and neomycin/resistance gene. Lentiviral vectors were co-transduced with MD2G and PAX2 in 293T cells (5 million cells/10 cm plate) with 25 µl of XtremeGene9 (Millipore Sigma, #6365787001) and supernatant was harvested at 48 and 72 hr post transfection. Target cells were transduced with the addition of 4 µg/ml polybrene (Santa Cruz, sc-134220). Infected cells were selected and maintained in 500 µg/ml G418 (Life Technologies, #10131027). lentiCas9-Blast was a gift from Feng Zhang (<xref ref-type="bibr" rid="bib73">Sanjana et al., 2014</xref>) (Addgene plasmid #52962). ipUSEPR was a gift from Francisco Sanchez-Rivera and Scott Lowe. sgRNAs were selected from the Brunello CRISPR database (<xref ref-type="bibr" rid="bib20">Doench et al., 2016</xref>). Four guides per gene were tested in Caco2 cells and the most efficient two sgRNAs/gene were used in subsequent experiments (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Knockout efficiency was determined by next-generation amplicon sequencing (Genewiz).</p></sec><sec id="s4-5"><title>Pseudovirus</title><p>Recombinant VSV-based and HIV-1-based SARS-CoV-2 pseudovirus was generated as described previously (<xref ref-type="bibr" rid="bib74">Schmidt et al., 2020</xref>). To generate rVSVΔG/SARS-CoV-2 pseudovirus<italic>,</italic> 293T cells (12 million cells/15 cm plate) were transfected with 12.5 µg pSARS-CoV-2<sub>Δ19</sub>, and 24 hr post transfection, were infected with VSV-G-complemented rVSVΔG virus at an MOI of 1. Supernatant was collected 16 hr post infection, centrifuged at 350 <italic>g</italic> × 10 min, filtered through a 0.45 µm filter, and concentrated using Lenti-X-Concentrator (Takara Bio). Prior to infection of target cells, the viral stock was incubated with anti-VSV-G antibody (3 µg/ml) for 1 hr at 37°C to neutralize contaminating rVSVΔG/NG/NanoLuc/VSV-G particles.</p><p>To generate HIV-1<sub>NL</sub>/SARS-CoV-2 pseudovirus, 293T cells (12 million cells/15 cm plate) were co-transfected with 15.75 µg CCNanoLuc/GFP, 15.75 µg HIV-1<sub>NL</sub> GagPol, and 5.625 µg CMV-SARS-CoV-2-S, using 50 µl per 15 cm plate X-tremeGENE 9 (Sigma-Aldrich, 8724121001). Media was changed at 24 hr post transfection, and supernatant was collected at 48 and 72 hr. Centrifuged and filtered pseudovirus was concentrated with Lenti-X-Concentrator or with 40% (w/v) PEG-8000, 1.2 M NaCl, pH 7.2.</p></sec><sec id="s4-6"><title>Incucyte</title><p>Cells were imaged and analyzed using an Incucyte ZOOM (Essen BioScience). Four fields of view per well were averaged and 3–6 wells/condition were assayed in each experiment. Confluence was calculated from brightfield images, GFP/NeonGreen object confluence was calculated from green fluorescent images taken with 400 ms exposure time, and GFP+ fractional area is the ratio of these variables.</p></sec><sec id="s4-7"><title>Luciferase assay</title><p>Following pseudovirus infection, cells were washed twice with PBS, which was subsequently aspirated. Lysis buffer (Promega, E1531) was added (50 µl/well) and incubated rotating for 15 min at room temperature. NanoGlo Substrate (Promega, N1130) was diluted 1:50 in assay buffer and 25 µl/well was added and incubated for an additional 15 min. Samples were transferred to a white, opaque-bottom 96-well plate and luminescence was read using a BMG Labtech FLUOstar Omega plate reader.</p></sec><sec id="s4-8"><title>Clotting assays</title><p>Pooled normal human plasma was obtained from Pacific Hemostasis (VWR #95059–698). Factor X and prothrombin-deficient plasma were obtained from Haematologic Technologies (#FX-ID and #FII-ID). Russell’s viper venom test was performed with 10 µg/ml snake venom from <italic>Vipera russelli</italic> (RVV, Sigma-Aldrich #V2501) diluted in Tris buffer (20 mM Tris-HCl, 150 mM NaCl, 14 mM CaCl<sub>2</sub>, pH 7.5). Pre-warmed plasma was mixed with pre-warmed dilute venom (100 µl each) and monitored for visible clotting at 37°C. Prothrombin time was determined by mixing 100 µl pre-warmed plasma with 200 µl pre-warmed thromboplastin (VWR #95059–802) and monitoring for visible clotting at 37°C.</p></sec><sec id="s4-9"><title>hPSC lung organoids</title><p>The hPSC-derived lung organoids were differentiated and cultured as described previously (<xref ref-type="bibr" rid="bib28">Han et al., 2021</xref>). Briefly, hPSCs were differentiated into endoderm in serum-free differentiation (SFD) medium (DMEM/F12 (3:1) (Life Technologies) supplemented with 1 × N2 (Life Technologies), 1 × B27 (Life Technologies), 50 μg/ml ascorbic acid, 2 mM Glutamax (Gibco), 0.4 μM monothioglycerol and 0.05% BSA) in a 5% O<sub>2</sub> incubator; followed by 10 μM Y-27632, 0.5 ng/ml human BMP4 (R&amp;D Systems), 2.5 ng/ml human bFGF and 100 ng/ml human activin A (R&amp;D Systems) for 3 days; and subsequently single cells were plated on fibronectin-coated plates. Differentiation to anterior foregut endoderm was performed with SFD with 1.5 μM dorsomorphin dihydrochloride (R&amp;D Systems) and 10 μM SB431542 (R&amp;D Systems) for 3 days, and then 10 μM SB431542 and 1 μM IWP2 (R&amp;D Systems) treatment for 3 days. Differentiation to early stage lung progenitor cells was accomplished by treatment with 3 μM CHIR99021 (CHIR, Stem-RD), 10 ng/ml human FGF10, 10 ng/ml human KGF, 10 ng/ml human BMP4, and 50–60 nM all-trans retinoic acid (ATRA) in a 5% CO<sub>2</sub>/air incubator. Differentiation to late-stage lung progenitor cells, cells were treated with SFD containing 3 μM CHIR99021, 10 ng/ml human FGF10, 10 ng/ml human FGF7, 10 ng/ml human BMP4 and 50 nM ATRA on fibronectin-coated plates, and subsequently maintained for 1 week in SFD medium containing 3 μM CHIR99021, 10 ng/ml human FGF10 and 10 ng/ml human KGF, in a 5% CO<sub>2</sub>/air incubator. Mature lung organoids were generated by growing late-stage lung progenitor cells in 90% Matrigel in SFD medium containing 3 μM CHIR99021, 10 ng/ml human FGF10, 10 ng/ml human KGF, 50 nM dexamethasone, 0.1 mM 8-bromo-cAMP (Sigma-Aldrich), and 0.1 mM IBMX (3,7-dihydro-1-methyl-3-(2-methylpropyl)-1<italic>H</italic>-purine-2,6-dione; Sigma-Aldrich) for ~20 days.</p></sec><sec id="s4-10"><title>SARS-CoV-2 virus infection</title><p>SARS-CoV-2 was maintained and infections were performed as described previously (<xref ref-type="bibr" rid="bib83">Tang et al., 2021b</xref>). SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/l D-glucose, 4 mM L-glutamine, 10 mM non-essential amino acids, 1 mM sodium pyruvate, and 10 mM HEPES. MOI of SARS-CoV-2 was determined by plaque assay in Vero E6 cells in Minimum Essential Media supplemented with 2% FBS, 4 mM L-glutamine, 0.2% BSA, 10 mM HEPES and 0.12% NaHCO<sub>3</sub>, and 0.7% agar.</p><p>All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements.</p><p>At 24 or 48 hpi, RNA was extracted with TRIzol and Direct-zol RNA Miniprep Plus kit (Zymo Research). SARS-CoV-2-N and SARS-CoV-2-E transcripts were quantified by two-step qRT-PCR using LunaScript RT SuperMix Kit (E3010L) for c-DNA synthesis and Luna Universal qPCR Master Mix (NEB #M3003) for RT-qPCR. qRT-PCRs were performed on CFX384 Touch Real-Time PCR Detection System (Bio-Rad). Primers specific for the <italic>N</italic> gene (SARS-CoV-2-N-F: <named-content content-type="sequence">TAATCAGACAAGGAACTGATTA</named-content>, SARS-CoV-2-N-R: <named-content content-type="sequence">CGAAGGTGTGACTTCCATG</named-content>), for the <italic>E</italic> gene (SARS-CoV-2-E-F: <named-content content-type="sequence">ACAGGTACGTTAATAGTTAATAGCGT</named-content>, SARS-CoV-2-E-R: <named-content content-type="sequence">ATATTGCAGCAGTACGCACACA</named-content>), as well as internal control human 18S (Forward: <named-content content-type="sequence">GGCCCTGTAATTGGAATGAGTC</named-content>, Reverse: <named-content content-type="sequence">CCAAGATCCAACTACGAGCTT</named-content>) were used. The delta-delta-cycle threshold (ΔΔCT) was determined relative to 18S and vehicle-treated samples.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is on the scientific advisory board for Miromatrix Inc and is a consultant and speaker for Alnylam Inc</p></fn><fn fn-type="COI-statement" id="conf4"><p>is a founder and member of the SAB of Agios Pharmaceuticals and a founder and former member of the SAB of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing novel therapies for cancer. Holds equity in Agios. Lewis Cantley's laboratory also received some financial support from Ravenna Pharmaceuticals</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Resources</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Funding acquisition, Supervision</p></fn><fn fn-type="con" id="con12"><p>Funding acquisition, Investigation, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-77444-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Graphical abstract: Positive feedback in SARS-CoV-2 infection and coagulopathy.</title><p>In this study, we investigated the role of coagulation factors in SARS-CoV-2 infection. Hyperactivated coagulation is a feature of COVID-19 pathology. Coagulation factors, including factor Xa and thrombin, can cleave SARS-CoV-2 spike. This activity can exacerbate infection by enhancing viral entry. Lastly, we show that a subset of protease inhibitors with anticoagulant properties, such as nafamostat, also have the potential to block host-mediated spike activation by multiple human proteases.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-77444-supp1-v2.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All new plasmids will be made available through Addgene.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank Pilar Mendoza (Rockefeller University), John Blenis (WCMC), Elena Piskounova (WCMC), Tim McGraw (WCMC), Marco Straus (Cornell University), Tomer Yaron (WCMC), and all members of the Cantley Lab for insightful discussion and helpful comments. We thank Paul Bieniasz (Rockefeller University) and Theodora Hatziioannou (Rockefeller University) for providing reagents and helping to establish the pseudovirus platform in our laboratory. We thank Danielle Bulaon (Weill Cornell) for provisioning inhibitors, Benjamin tenOever (Mount Sinai) for providing Vero cells, and Francisco Sanchez-Rivera and Scott Lowe (MSKCC) for the ipUSEPR plasmid. This work was funded in part by the National Institute of Health research grants R01AI35270 (to GW) and R35 CA197588 (to LCC) and the Pershing Square Foundation (LCC).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akizawa</surname><given-names>T</given-names></name><name><surname>Koshikawa</surname><given-names>S</given-names></name><name><surname>Ota</surname><given-names>K</given-names></name><name><surname>Kazama</surname><given-names>M</given-names></name><name><surname>Mimura</surname><given-names>N</given-names></name><name><surname>Hirasawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding</article-title><source>Nephron</source><volume>64</volume><fpage>376</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1159/000187357</pub-id><pub-id pub-id-type="pmid">8341382</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Rathnasinghe</surname><given-names>R</given-names></name><name><surname>Schotsaert</surname><given-names>M</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model</article-title><source>MBio</source><volume>12</volume><elocation-id>e02648-20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02648-20</pub-id><pub-id pub-id-type="pmid">33653892</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><name><surname>El Sahly</surname><given-names>HM</given-names></name><name><surname>Essink</surname><given-names>B</given-names></name><name><surname>Kotloff</surname><given-names>K</given-names></name><name><surname>Frey</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><name><surname>Diemert</surname><given-names>D</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>McGettigan</surname><given-names>J</given-names></name><name><surname>Khetan</surname><given-names>S</given-names></name><name><surname>Segall</surname><given-names>N</given-names></name><name><surname>Solis</surname><given-names>J</given-names></name><name><surname>Brosz</surname><given-names>A</given-names></name><name><surname>Fierro</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>H</given-names></name><name><surname>Neuzil</surname><given-names>K</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>P</given-names></name><name><surname>Janes</surname><given-names>H</given-names></name><name><surname>Follmann</surname><given-names>D</given-names></name><name><surname>Marovich</surname><given-names>M</given-names></name><name><surname>Mascola</surname><given-names>J</given-names></name><name><surname>Polakowski</surname><given-names>L</given-names></name><name><surname>Ledgerwood</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Pajon</surname><given-names>R</given-names></name><name><surname>Knightly</surname><given-names>C</given-names></name><name><surname>Leav</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Ivarsson</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>New England Journal of Medicine</source><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baugh</surname><given-names>RJ</given-names></name><name><surname>Broze</surname><given-names>GJ</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>4378</fpage><lpage>4386</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.8.4378</pub-id><pub-id pub-id-type="pmid">9468488</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>VC</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</article-title><source>PNAS</source><volume>106</volume><fpage>5871</fpage><lpage>5876</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809524106</pub-id><pub-id pub-id-type="pmid">19321428</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S</given-names></name><name><surname>Madu</surname><given-names>I</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Elastase-mediated activation of the severe acute respiratory syndrome coronavirus spike protein at discrete sites within the S2 domain</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>22758</fpage><lpage>22763</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.103275</pub-id><pub-id pub-id-type="pmid">20507992</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benton</surname><given-names>DJ</given-names></name><name><surname>Wrobel</surname><given-names>AG</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Roustan</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Rosenthal</surname><given-names>PB</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion</article-title><source>Nature</source><volume>588</volume><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2772-0</pub-id><pub-id pub-id-type="pmid">32942285</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Schaffitzel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The SARS-CoV-2 spike protein: balancing stability and infectivity</article-title><source>Cell Research</source><volume>30</volume><fpage>1059</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00430-4</pub-id><pub-id pub-id-type="pmid">33139926</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestle</surname><given-names>D</given-names></name><name><surname>Heindl</surname><given-names>MR</given-names></name><name><surname>Limburg</surname><given-names>H</given-names></name><name><surname>Van Lam van</surname><given-names>T</given-names></name><name><surname>Pilgram</surname><given-names>O</given-names></name><name><surname>Moulton</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>DA</given-names></name><name><surname>Hardes</surname><given-names>K</given-names></name><name><surname>Eickmann</surname><given-names>M</given-names></name><name><surname>Dolnik</surname><given-names>O</given-names></name><name><surname>Rohde</surname><given-names>C</given-names></name><name><surname>Klenk</surname><given-names>H-D</given-names></name><name><surname>Garten</surname><given-names>W</given-names></name><name><surname>Steinmetzer</surname><given-names>T</given-names></name><name><surname>Böttcher-Friebertshäuser</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells</article-title><source>Life Science Alliance</source><volume>3</volume><elocation-id>e202000786</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202000786</pub-id><pub-id pub-id-type="pmid">32703818</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummel-Ziedins</surname><given-names>KE</given-names></name><name><surname>Orfeo</surname><given-names>T</given-names></name><name><surname>Gissel</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>KG</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e29178</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029178</pub-id><pub-id pub-id-type="pmid">22247769</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capell</surname><given-names>WH</given-names></name><name><surname>Barnathan</surname><given-names>ES</given-names></name><name><surname>Piazza</surname><given-names>G</given-names></name><name><surname>Spyropoulos</surname><given-names>AC</given-names></name><name><surname>Hsia</surname><given-names>J</given-names></name><name><surname>Bull</surname><given-names>S</given-names></name><name><surname>Lipardi</surname><given-names>C</given-names></name><name><surname>Sugarmann</surname><given-names>C</given-names></name><name><surname>Suh</surname><given-names>E</given-names></name><name><surname>Rao</surname><given-names>JP</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name><name><surname>Bonaca</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study</article-title><source>American Heart Journal</source><volume>235</volume><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2021.02.001</pub-id><pub-id pub-id-type="pmid">33577800</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y-W</given-names></name><name><surname>Huang</surname><given-names>SX</given-names></name><name><surname>de Carvalho</surname><given-names>ALRT</given-names></name><name><surname>Ho</surname><given-names>S-H</given-names></name><name><surname>Islam</surname><given-names>MN</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Ciancanelli</surname><given-names>M</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Bhattacharya</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>AF</given-names></name><name><surname>Palermo</surname><given-names>LM</given-names></name><name><surname>Porotto</surname><given-names>M</given-names></name><name><surname>Moscona</surname><given-names>A</given-names></name><name><surname>Snoeck</surname><given-names>H-W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A three-dimensional model of human lung development and disease from pluripotent stem cells</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/ncb3510</pub-id><pub-id pub-id-type="pmid">28436965</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Poran</surname><given-names>A</given-names></name><name><surname>Unni</surname><given-names>AM</given-names></name><name><surname>Huang</surname><given-names>SX</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Snoeck</surname><given-names>HW</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>674</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1084/jem.20181155</pub-id><pub-id pub-id-type="pmid">30737256</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Stecker</surname><given-names>E</given-names></name><name><surname>A Warden</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges</article-title><source>Journal of the American Heart Association</source><volume>9</volume><elocation-id>e017559</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.120.017559</pub-id><pub-id pub-id-type="pmid">32538234</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>VCC</given-names></name><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Woo</surname><given-names>PCY</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</article-title><source>Clinical Microbiology Reviews</source><volume>20</volume><fpage>660</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1128/CMR.00023-07</pub-id><pub-id pub-id-type="pmid">17934078</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>J</given-names></name><name><surname>Motoyama</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist</article-title><source>Thrombosis and Haemostasis</source><volume>75</volume><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">8701416</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis</article-title><source>Frontiers in Pharmacology</source><volume>12</volume><elocation-id>708665</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.708665</pub-id><pub-id pub-id-type="pmid">34290613</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuker</surname><given-names>A</given-names></name><name><surname>Tseng</surname><given-names>EK</given-names></name><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><name><surname>Angchaisuksiri</surname><given-names>P</given-names></name><name><surname>Blair</surname><given-names>C</given-names></name><name><surname>Dane</surname><given-names>K</given-names></name><name><surname>Davila</surname><given-names>J</given-names></name><name><surname>DeSancho</surname><given-names>MT</given-names></name><name><surname>Diuguid</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>DO</given-names></name><name><surname>Kahn</surname><given-names>SR</given-names></name><name><surname>Klok</surname><given-names>FA</given-names></name><name><surname>Lee</surname><given-names>AI</given-names></name><name><surname>Neumann</surname><given-names>I</given-names></name><name><surname>Pai</surname><given-names>A</given-names></name><name><surname>Pai</surname><given-names>M</given-names></name><name><surname>Righini</surname><given-names>M</given-names></name><name><surname>Sanfilippo</surname><given-names>KM</given-names></name><name><surname>Siegal</surname><given-names>D</given-names></name><name><surname>Skara</surname><given-names>M</given-names></name><name><surname>Touri</surname><given-names>K</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Bou Akl</surname><given-names>I</given-names></name><name><surname>Boulos</surname><given-names>M</given-names></name><name><surname>Brignardello-Petersen</surname><given-names>R</given-names></name><name><surname>Charide</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>M</given-names></name><name><surname>Dearness</surname><given-names>K</given-names></name><name><surname>Darzi</surname><given-names>AJ</given-names></name><name><surname>Kolb</surname><given-names>P</given-names></name><name><surname>Colunga-Lozano</surname><given-names>LE</given-names></name><name><surname>Mansour</surname><given-names>R</given-names></name><name><surname>Morgano</surname><given-names>GP</given-names></name><name><surname>Morsi</surname><given-names>RZ</given-names></name><name><surname>Noori</surname><given-names>A</given-names></name><name><surname>Piggott</surname><given-names>T</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Roldan</surname><given-names>Y</given-names></name><name><surname>Schünemann</surname><given-names>F</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Solo</surname><given-names>K</given-names></name><name><surname>Ventresca</surname><given-names>M</given-names></name><name><surname>Wiercioch</surname><given-names>W</given-names></name><name><surname>Mustafa</surname><given-names>RA</given-names></name><name><surname>Schünemann</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19</article-title><source>Blood Advances</source><volume>5</volume><fpage>872</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003763</pub-id><pub-id pub-id-type="pmid">33560401</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damalanka</surname><given-names>VC</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Karmakar</surname><given-names>P</given-names></name><name><surname>O’Donoghue</surname><given-names>AJ</given-names></name><name><surname>La Greca</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Pant</surname><given-names>SM</given-names></name><name><surname>Helander</surname><given-names>J</given-names></name><name><surname>Klefström</surname><given-names>J</given-names></name><name><surname>Craik</surname><given-names>CS</given-names></name><name><surname>Janetka</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>480</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01536</pub-id><pub-id pub-id-type="pmid">30571119</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Fusi</surname><given-names>N</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Wilen</surname><given-names>C</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Listgarten</surname><given-names>J</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Kao</surname><given-names>RY</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity</article-title><source>Biochemical and Biophysical Research Communications</source><volume>359</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.05.092</pub-id><pub-id pub-id-type="pmid">17533109</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Hitomi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin</article-title><source>Biochimica et Biophysica Acta (BBA) - Enzymology</source><volume>661</volume><fpage>342</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/0005-2744(81)90023-1</pub-id><pub-id pub-id-type="pmid">6271224</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>X-Y</given-names></name><name><surname>Li</surname><given-names>J-L</given-names></name><name><surname>Yang</surname><given-names>X-L</given-names></name><name><surname>Chmura</surname><given-names>AA</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Epstein</surname><given-names>JH</given-names></name><name><surname>Mazet</surname><given-names>JK</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y-J</given-names></name><name><surname>Luo</surname><given-names>C-M</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Crameri</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Wang</surname><given-names>L-F</given-names></name><name><surname>Daszak</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>Z-L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor</article-title><source>Nature</source><volume>503</volume><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/nature12711</pub-id><pub-id pub-id-type="pmid">24172901</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisbert</surname><given-names>TW</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Jahrling</surname><given-names>PB</given-names></name><name><surname>Davis</surname><given-names>KJ</given-names></name><name><surname>Kagan</surname><given-names>E</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event</article-title><source>The Journal of Infectious Diseases</source><volume>188</volume><fpage>1618</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1086/379724</pub-id><pub-id pub-id-type="pmid">14639531</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Soilleux</surname><given-names>E</given-names></name><name><surname>Pfefferle</surname><given-names>S</given-names></name><name><surname>Steffen</surname><given-names>I</given-names></name><name><surname>Tsegaye</surname><given-names>TS</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Gnirss</surname><given-names>K</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response</article-title><source>Journal of Virology</source><volume>85</volume><fpage>4122</fpage><lpage>4134</lpage><pub-id pub-id-type="doi">10.1128/JVI.02232-10</pub-id><pub-id pub-id-type="pmid">21325420</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>B</given-names></name><name><surname>Ogasawara</surname><given-names>T</given-names></name><name><surname>Toyoda</surname><given-names>T</given-names></name><name><surname>Inocencio</surname><given-names>NM</given-names></name><name><surname>Hamaguchi</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>An endoprotease homologous to the blood clotting factor X as a determinant of viral tropism in chick embryo</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>4189</fpage><lpage>4195</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07643.x</pub-id><pub-id pub-id-type="pmid">2174359</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>DO</given-names></name><name><surname>Brennan-Rieder</surname><given-names>D</given-names></name><name><surname>Ngo</surname><given-names>B</given-names></name><name><surname>Kory</surname><given-names>P</given-names></name><name><surname>Confalonieri</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Iglesias</surname><given-names>J</given-names></name><name><surname>Dube</surname><given-names>M</given-names></name><name><surname>Nanda</surname><given-names>N</given-names></name><name><surname>In</surname><given-names>GK</given-names></name><name><surname>Arkfeld</surname><given-names>D</given-names></name><name><surname>Chaudhary</surname><given-names>P</given-names></name><name><surname>Campese</surname><given-names>VM</given-names></name><name><surname>Hanna</surname><given-names>DL</given-names></name><name><surname>Sawcer</surname><given-names>D</given-names></name><name><surname>Ehresmann</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>D</given-names></name><name><surname>Smorgorzewski</surname><given-names>M</given-names></name><name><surname>Amstrong</surname><given-names>A</given-names></name><name><surname>Vinjevoll</surname><given-names>EH</given-names></name><name><surname>Dasgupta</surname><given-names>R</given-names></name><name><surname>Sattler</surname><given-names>FR</given-names></name><name><surname>Mussini</surname><given-names>C</given-names></name><name><surname>Mitjà</surname><given-names>O</given-names></name><name><surname>Soriano</surname><given-names>V</given-names></name><name><surname>Peschanski</surname><given-names>N</given-names></name><name><surname>Hayem</surname><given-names>G</given-names></name><name><surname>Piccirillo</surname><given-names>MC</given-names></name><name><surname>Lobo-Ferreira</surname><given-names>A</given-names></name><name><surname>Rivero</surname><given-names>IB</given-names></name><name><surname>Hung</surname><given-names>IFH</given-names></name><name><surname>Rendell</surname><given-names>M</given-names></name><name><surname>Ditmore</surname><given-names>S</given-names></name><name><surname>Varon</surname><given-names>J</given-names></name><name><surname>Marik</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Importance of Understanding the Stages of COVID-19 in Treatment and Trials</article-title><source>AIDS Reviews</source><volume>23</volume><pub-id pub-id-type="doi">10.24875/AIDSRev.200001261</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Yaron</surname><given-names>TM</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Bram</surname><given-names>Y</given-names></name><name><surname>Richardson</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Redmond</surname><given-names>D</given-names></name><name><surname>Houghton</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>D-HT</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jessurun</surname><given-names>J</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Pan</surname><given-names>FC</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of SARS-CoV-2 inhibitors using lung and colonic organoids</article-title><source>Nature</source><volume>589</volume><fpage>270</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2901-9</pub-id><pub-id pub-id-type="pmid">33116299</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellenbart</surname><given-names>EL</given-names></name><name><surname>Faulkenberg</surname><given-names>KD</given-names></name><name><surname>Finks</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evaluation of bleeding in patients receiving direct oral anticoagulants</article-title><source>Vascular Health and Risk Management</source><volume>13</volume><fpage>325</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.2147/VHRM.S121661</pub-id><pub-id pub-id-type="pmid">28860793</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>64</volume><elocation-id>e00754-20</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00754-20</pub-id><pub-id pub-id-type="pmid">32312781</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Hofmann-Winkler</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Sørensen</surname><given-names>LK</given-names></name><name><surname>Søgaard</surname><given-names>OS</given-names></name><name><surname>Hasselstrøm</surname><given-names>JB</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Hempel</surname><given-names>T</given-names></name><name><surname>Raich</surname><given-names>L</given-names></name><name><surname>Olsson</surname><given-names>S</given-names></name><name><surname>Danov</surname><given-names>O</given-names></name><name><surname>Jonigk</surname><given-names>D</given-names></name><name><surname>Yamazoe</surname><given-names>T</given-names></name><name><surname>Yamatsuta</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Noé</surname><given-names>F</given-names></name><name><surname>Kjolby</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>A</given-names></name><name><surname>Sheltzer</surname><given-names>JM</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity</article-title><source>EBioMedicine</source><volume>65</volume><elocation-id>103255</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103255</pub-id><pub-id pub-id-type="pmid">33676899</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SXL</given-names></name><name><surname>Islam</surname><given-names>MN</given-names></name><name><surname>O’Neill</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y-G</given-names></name><name><surname>Chen</surname><given-names>Y-W</given-names></name><name><surname>Mumau</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>MD</given-names></name><name><surname>Vunjak-Novakovic</surname><given-names>G</given-names></name><name><surname>Bhattacharya</surname><given-names>J</given-names></name><name><surname>Snoeck</surname><given-names>H-W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficient generation of lung and airway epithelial cells from human pluripotent stem cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nbt.2754</pub-id><pub-id pub-id-type="pmid">24291815</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection</article-title><source>Journal of Virology</source><volume>93</volume><elocation-id>e01815-18</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01815-18</pub-id><pub-id pub-id-type="pmid">30626688</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Goldstein</surname><given-names>ME</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name><name><surname>Straus</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation</article-title><source>Journal of Visualized Experiments</source><volume>10</volume><elocation-id>3791</elocation-id><pub-id pub-id-type="doi">10.3791/58892</pub-id><pub-id pub-id-type="pmid">30688313</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>André</surname><given-names>NM</given-names></name><name><surname>Chappie</surname><given-names>JS</given-names></name><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop</article-title><source>Journal of Molecular Biology</source><volume>432</volume><fpage>3309</fpage><lpage>3325</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2020.04.009</pub-id><pub-id pub-id-type="pmid">32320687</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>J</given-names></name><name><surname>Millet</surname><given-names>J</given-names></name><name><surname>Whittaker</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site</article-title><source>SSRN</source><volume>3581359</volume><elocation-id>3581359</elocation-id><pub-id pub-id-type="doi">10.2139/ssrn.3581359</pub-id><pub-id pub-id-type="pmid">32714113</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2020">2020c</year><article-title>Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site</article-title><source>IScience</source><volume>23</volume><elocation-id>101212</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.101212</pub-id><pub-id pub-id-type="pmid">32512386</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Bailey</surname><given-names>AL</given-names></name><name><surname>Kalveram</surname><given-names>B</given-names></name><name><surname>Lokugamage</surname><given-names>KG</given-names></name><name><surname>Muruato</surname><given-names>A</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Juelich</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>JK</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bopp</surname><given-names>N</given-names></name><name><surname>Schindewolf</surname><given-names>C</given-names></name><name><surname>Vu</surname><given-names>M</given-names></name><name><surname>Vanderheiden</surname><given-names>A</given-names></name><name><surname>Winkler</surname><given-names>ES</given-names></name><name><surname>Swetnam</surname><given-names>D</given-names></name><name><surname>Plante</surname><given-names>JA</given-names></name><name><surname>Aguilar</surname><given-names>P</given-names></name><name><surname>Plante</surname><given-names>KS</given-names></name><name><surname>Popov</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Routh</surname><given-names>AL</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Ku</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>Z</given-names></name><name><surname>Debbink</surname><given-names>K</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Shi</surname><given-names>P-Y</given-names></name><name><surname>Freiberg</surname><given-names>AN</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis</article-title><source>Nature</source><volume>591</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03237-4</pub-id><pub-id pub-id-type="pmid">33494095</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>Y-W</given-names></name><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Kido</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name><name><surname>Bruzzone</surname><given-names>R</given-names></name><name><surname>Altmeyer</surname><given-names>R</given-names></name><name><surname>Snounou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e7870</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007870</pub-id><pub-id pub-id-type="pmid">19924243</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanade</surname><given-names>GD</given-names></name><name><surname>Pingale</surname><given-names>KD</given-names></name><name><surname>Karpe</surname><given-names>YA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing</article-title><source>Journal of Virology</source><volume>92</volume><elocation-id>e01853-17</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01853-17</pub-id><pub-id pub-id-type="pmid">29321328</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keck</surname><given-names>T</given-names></name><name><surname>Balcom</surname><given-names>JH</given-names></name><name><surname>Antoniu</surname><given-names>BA</given-names></name><name><surname>Lewandrowski</surname><given-names>K</given-names></name><name><surname>Warshaw</surname><given-names>AL</given-names></name><name><surname>Castillo</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis</article-title><source>Surgery</source><volume>130</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1067/msy.2001.115827</pub-id><pub-id pub-id-type="pmid">11490346</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kido</surname><given-names>H</given-names></name><name><surname>Niwa</surname><given-names>Y</given-names></name><name><surname>Beppu</surname><given-names>Y</given-names></name><name><surname>Towatari</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus</article-title><source>Advances in Enzyme Regulation</source><volume>36</volume><fpage>325</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/0065-2571(95)00016-X</pub-id><pub-id pub-id-type="pmid">8869754</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kipshidze</surname><given-names>N</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>White</surname><given-names>CJ</given-names></name><name><surname>Kipshidze</surname><given-names>N</given-names></name><name><surname>Siddiqui</surname><given-names>F</given-names></name><name><surname>Lattimer</surname><given-names>CR</given-names></name><name><surname>Carter</surname><given-names>CA</given-names></name><name><surname>Fareed</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Viral Coagulopathy in Patients With COVID-19: Treatment and Care</article-title><source>Clinical and Applied Thrombosis/Hemostasis</source><volume>26</volume><elocation-id>1076029620936776</elocation-id><pub-id pub-id-type="doi">10.1177/1076029620936776</pub-id><pub-id pub-id-type="pmid">32687449</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Terao</surname><given-names>T</given-names></name><name><surname>Maki</surname><given-names>M</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Diagnosis and management of acute obstetrical DIC</article-title><source>Seminars in Thrombosis and Hemostasis</source><volume>27</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1055/s-2001-14076</pub-id><pub-id pub-id-type="pmid">11372771</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>KO</given-names></name><name><surname>Li</surname><given-names>KK</given-names></name><name><surname>Wei</surname><given-names>WI</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>SYS</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey</article-title><source>International Journal of Nursing Studies</source><volume>114</volume><elocation-id>103854</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijnurstu.2020.103854</pub-id><pub-id pub-id-type="pmid">33326864</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Tu</surname><given-names>P</given-names></name><name><surname>Beitsch</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review</article-title><source>Vaccines</source><volume>9</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010016</pub-id><pub-id pub-id-type="pmid">33396832</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>RD</given-names></name><name><surname>de Barros E Silva</surname><given-names>PGM</given-names></name><name><surname>Furtado</surname><given-names>RHM</given-names></name><name><surname>Macedo</surname><given-names>AVS</given-names></name><name><surname>Bronhara</surname><given-names>B</given-names></name><name><surname>Damiani</surname><given-names>LP</given-names></name><name><surname>Barbosa</surname><given-names>LM</given-names></name><name><surname>de Aveiro Morata</surname><given-names>J</given-names></name><name><surname>Ramacciotti</surname><given-names>E</given-names></name><name><surname>de Aquino Martins</surname><given-names>P</given-names></name><name><surname>de Oliveira</surname><given-names>AL</given-names></name><name><surname>Nunes</surname><given-names>VS</given-names></name><name><surname>Ritt</surname><given-names>LEF</given-names></name><name><surname>Rocha</surname><given-names>AT</given-names></name><name><surname>Tramujas</surname><given-names>L</given-names></name><name><surname>Santos</surname><given-names>SV</given-names></name><name><surname>Diaz</surname><given-names>DRA</given-names></name><name><surname>Viana</surname><given-names>LS</given-names></name><name><surname>Melro</surname><given-names>LMG</given-names></name><name><surname>de Alcântara Chaud</surname><given-names>MS</given-names></name><name><surname>Figueiredo</surname><given-names>EL</given-names></name><name><surname>Neuenschwander</surname><given-names>FC</given-names></name><name><surname>Dracoulakis</surname><given-names>MDA</given-names></name><name><surname>Lima</surname><given-names>RGSD</given-names></name><name><surname>de Souza Dantas</surname><given-names>VC</given-names></name><name><surname>Fernandes</surname><given-names>ACS</given-names></name><name><surname>Gebara</surname><given-names>OCE</given-names></name><name><surname>Hernandes</surname><given-names>ME</given-names></name><name><surname>Queiroz</surname><given-names>DAR</given-names></name><name><surname>Veiga</surname><given-names>VC</given-names></name><name><surname>Canesin</surname><given-names>MF</given-names></name><name><surname>de Faria</surname><given-names>LM</given-names></name><name><surname>Feitosa-Filho</surname><given-names>GS</given-names></name><name><surname>Gazzana</surname><given-names>MB</given-names></name><name><surname>Liporace</surname><given-names>IL</given-names></name><name><surname>de Oliveira Twardowsky</surname><given-names>A</given-names></name><name><surname>Maia</surname><given-names>LN</given-names></name><name><surname>Machado</surname><given-names>FR</given-names></name><name><surname>de Matos Soeiro</surname><given-names>A</given-names></name><name><surname>Conceição-Souza</surname><given-names>GE</given-names></name><name><surname>Armaganijan</surname><given-names>L</given-names></name><name><surname>Guimarães</surname><given-names>PO</given-names></name><name><surname>Rosa</surname><given-names>RG</given-names></name><name><surname>Azevedo</surname><given-names>LCP</given-names></name><name><surname>Alexander</surname><given-names>JH</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Cavalcanti</surname><given-names>AB</given-names></name><name><surname>Berwanger</surname><given-names>O</given-names></name><collab>ACTION Coalition COVID-19 Brazil IV Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial</article-title><source>Lancet (London, England)</source><volume>397</volume><fpage>2253</fpage><lpage>2263</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01203-4</pub-id><pub-id pub-id-type="pmid">34097856</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Mizurini</surname><given-names>DM</given-names></name><name><surname>Assumpção</surname><given-names>TCF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Kotsyfakis</surname><given-names>M</given-names></name><name><surname>Ribeiro</surname><given-names>JMC</given-names></name><name><surname>Monteiro</surname><given-names>RQ</given-names></name><name><surname>Francischetti</surname><given-names>IMB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo</article-title><source>Blood</source><volume>122</volume><fpage>4094</fpage><lpage>4106</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-08-517474</pub-id><pub-id pub-id-type="pmid">24159172</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madu</surname><given-names>IG</given-names></name><name><surname>Roth</surname><given-names>SL</given-names></name><name><surname>Belouzard</surname><given-names>S</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide</article-title><source>Journal of Virology</source><volume>83</volume><fpage>7411</fpage><lpage>7421</lpage><pub-id pub-id-type="doi">10.1128/JVI.00079-09</pub-id><pub-id pub-id-type="pmid">19439480</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>S</given-names></name><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>Kita</surname><given-names>H</given-names></name><name><surname>Miyatake</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Mizobuchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy</article-title><source>The International Journal of Artificial Organs</source><volume>39</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.5301/ijao.5000465</pub-id><pub-id pub-id-type="pmid">26868216</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markland</surname><given-names>FS</given-names></name><name><surname>Swenson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Snake venom metalloproteinases</article-title><source>Toxicon</source><volume>62</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.09.004</pub-id><pub-id pub-id-type="pmid">23000249</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Ujike</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>S</given-names></name><name><surname>Tashiro</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection</article-title><source>PNAS</source><volume>102</volume><fpage>12543</fpage><lpage>12547</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503203102</pub-id><pub-id pub-id-type="pmid">16116101</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGonagle</surname><given-names>D</given-names></name><name><surname>O’Donnell</surname><given-names>JS</given-names></name><name><surname>Sharif</surname><given-names>K</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Bridgewood</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia</article-title><source>The Lancet. Rheumatology</source><volume>2</volume><fpage>e437</fpage><lpage>e445</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30121-1</pub-id><pub-id pub-id-type="pmid">32835247</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Yount</surname><given-names>BL</given-names><suffix>Jr</suffix></name><name><surname>Debbink</surname><given-names>K</given-names></name><name><surname>Agnihothram</surname><given-names>S</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Plante</surname><given-names>JA</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><name><surname>Ge</surname><given-names>X-Y</given-names></name><name><surname>Donaldson</surname><given-names>EF</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name><name><surname>Shi</surname><given-names>Z-L</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence</article-title><source>Nature Medicine</source><volume>21</volume><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1038/nm.3985</pub-id><pub-id pub-id-type="pmid">26552008</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Yount</surname><given-names>BL</given-names></name><name><surname>McAnarney</surname><given-names>ET</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Hale</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><name><surname>Anthony</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>B</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>e01774-19</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01774-19</pub-id><pub-id pub-id-type="pmid">31801868</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>JT</given-names></name><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Winakur</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications</article-title><source>Nature Reviews. Rheumatology</source><volume>16</volume><fpage>581</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-0474-5</pub-id><pub-id pub-id-type="pmid">32733003</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mészáros</surname><given-names>B</given-names></name><name><surname>Sámano-Sánchez</surname><given-names>H</given-names></name><name><surname>Alvarado-Valverde</surname><given-names>J</given-names></name><name><surname>Čalyševa</surname><given-names>J</given-names></name><name><surname>Martínez-Pérez</surname><given-names>E</given-names></name><name><surname>Alves</surname><given-names>R</given-names></name><name><surname>Shields</surname><given-names>DC</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Rippmann</surname><given-names>F</given-names></name><name><surname>Chemes</surname><given-names>LB</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications</article-title><source>Science Signaling</source><volume>14</volume><elocation-id>eabd0334</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.abd0334</pub-id><pub-id pub-id-type="pmid">33436497</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein</article-title><source>PNAS</source><volume>111</volume><fpage>15214</fpage><lpage>15219</lpage><pub-id pub-id-type="doi">10.1073/pnas.1407087111</pub-id><pub-id pub-id-type="pmid">25288733</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Sherwood</surname><given-names>R</given-names></name><name><surname>Ahfeldt</surname><given-names>T</given-names></name><name><surname>Lapey</surname><given-names>A</given-names></name><name><surname>Wain</surname><given-names>J</given-names></name><name><surname>Sicilian</surname><given-names>L</given-names></name><name><surname>Izvolsky</surname><given-names>K</given-names></name><name><surname>Musunuru</surname><given-names>K</given-names></name><name><surname>Cowan</surname><given-names>C</given-names></name><name><surname>Rajagopal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs</article-title><source>Cell Stem Cell</source><volume>10</volume><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.01.018</pub-id><pub-id pub-id-type="pmid">22482504</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nhamo</surname><given-names>G</given-names></name><name><surname>Chikodzi</surname><given-names>D</given-names></name><name><surname>Kunene</surname><given-names>HP</given-names></name><name><surname>Mashula</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs</article-title><source>Global Public Health</source><volume>16</volume><fpage>319</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1080/17441692.2020.1860249</pub-id><pub-id pub-id-type="pmid">33317389</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1620</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paccaly</surname><given-names>A</given-names></name><name><surname>Frick</surname><given-names>A</given-names></name><name><surname>Rohatagi</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Shukla</surname><given-names>U</given-names></name><name><surname>Rosenburg</surname><given-names>R</given-names></name><name><surname>Hinder</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure</article-title><source>Journal of Clinical Pharmacology</source><volume>46</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/0091270005281817</pub-id><pub-id pub-id-type="pmid">16397282</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Henao-Restrepo</surname><given-names>A-M</given-names></name><name><surname>Preziosi</surname><given-names>M-P</given-names></name><name><surname>Sathiyamoorthy</surname><given-names>V</given-names></name><name><surname>Abdool Karim</surname><given-names>Q</given-names></name><name><surname>Alejandria</surname><given-names>MM</given-names></name><name><surname>Hernández García</surname><given-names>C</given-names></name><name><surname>Kieny</surname><given-names>M-P</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>KS</given-names></name><name><surname>Roses Periago</surname><given-names>M</given-names></name><name><surname>Abi Hanna</surname><given-names>P</given-names></name><name><surname>Ader</surname><given-names>F</given-names></name><name><surname>Al-Bader</surname><given-names>AM</given-names></name><name><surname>Alhasawi</surname><given-names>A</given-names></name><name><surname>Allum</surname><given-names>E</given-names></name><name><surname>Alotaibi</surname><given-names>A</given-names></name><name><surname>Alvarez-Moreno</surname><given-names>CA</given-names></name><name><surname>Appadoo</surname><given-names>S</given-names></name><name><surname>Asiri</surname><given-names>A</given-names></name><name><surname>Aukrust</surname><given-names>P</given-names></name><name><surname>Barratt-Due</surname><given-names>A</given-names></name><name><surname>Bellani</surname><given-names>S</given-names></name><name><surname>Branca</surname><given-names>M</given-names></name><name><surname>Cappel-Porter</surname><given-names>HBC</given-names></name><name><surname>Cerrato</surname><given-names>N</given-names></name><name><surname>Chow</surname><given-names>TS</given-names></name><name><surname>Como</surname><given-names>N</given-names></name><name><surname>Eustace</surname><given-names>J</given-names></name><name><surname>García</surname><given-names>PJ</given-names></name><name><surname>Godbole</surname><given-names>S</given-names></name><name><surname>Gotuzzo</surname><given-names>E</given-names></name><name><surname>Griskevicius</surname><given-names>L</given-names></name><name><surname>Hamra</surname><given-names>R</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Hassany</surname><given-names>M</given-names></name><name><surname>Hutton</surname><given-names>D</given-names></name><name><surname>Irmansyah</surname><given-names>I</given-names></name><name><surname>Jancoriene</surname><given-names>L</given-names></name><name><surname>Kirwan</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Lennon</surname><given-names>P</given-names></name><name><surname>Lopardo</surname><given-names>G</given-names></name><name><surname>Lydon</surname><given-names>P</given-names></name><name><surname>Magrini</surname><given-names>N</given-names></name><name><surname>Maguire</surname><given-names>T</given-names></name><name><surname>Manevska</surname><given-names>S</given-names></name><name><surname>Manuel</surname><given-names>O</given-names></name><name><surname>McGinty</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>MT</given-names></name><name><surname>Mesa Rubio</surname><given-names>ML</given-names></name><name><surname>Miranda-Montoya</surname><given-names>MC</given-names></name><name><surname>Nel</surname><given-names>J</given-names></name><name><surname>Nunes</surname><given-names>EP</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Portolés</surname><given-names>A</given-names></name><name><surname>Rasmin</surname><given-names>MR</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Reges</surname><given-names>PPS</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Salami</surname><given-names>K</given-names></name><name><surname>Salvadori</surname><given-names>MI</given-names></name><name><surname>Sinani</surname><given-names>N</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>Stevanovikj</surname><given-names>M</given-names></name><name><surname>Tacconelli</surname><given-names>E</given-names></name><name><surname>Tikkinen</surname><given-names>KAO</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name><name><surname>Zaid</surname><given-names>H</given-names></name><name><surname>Røttingen</surname><given-names>J-A</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><collab>WHO Solidarity Trial Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2023184</pub-id><pub-id pub-id-type="pmid">33264556</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>G</given-names></name><name><surname>Mallery</surname><given-names>DL</given-names></name><name><surname>Albecka</surname><given-names>A</given-names></name><name><surname>Welch</surname><given-names>LG</given-names></name><name><surname>Cattin-Ortolá</surname><given-names>J</given-names></name><name><surname>Luptak</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>D</given-names></name><name><surname>McMahon</surname><given-names>HT</given-names></name><name><surname>Goodfellow</surname><given-names>IG</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>Munro</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>LC</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1009246</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009246</pub-id><pub-id pub-id-type="pmid">33493182</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Her</surname><given-names>C</given-names></name><name><surname>Min</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Jang</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation</article-title><source>The International Journal of Artificial Organs</source><volume>38</volume><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.5301/ijao.5000451</pub-id><pub-id pub-id-type="pmid">26728787</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>JL</given-names></name><name><surname>Pérez Marc</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>ED</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Swanson</surname><given-names>KA</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Kalina</surname><given-names>WV</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Frenck</surname><given-names>RW</given-names></name><name><surname>Hammitt</surname><given-names>LL</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Nell</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Ünal</surname><given-names>S</given-names></name><name><surname>Tresnan</surname><given-names>DB</given-names></name><name><surname>Mather</surname><given-names>S</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Şahin</surname><given-names>U</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Gruber</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title><source>New England Journal of Medicine</source><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prado</surname><given-names>M</given-names></name><name><surname>Solano-Trejos</surname><given-names>G</given-names></name><name><surname>Lomonte</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Acute physiopathological effects of honeybee (Apis mellifera) envenoming by subcutaneous route in a mouse model</article-title><source>Toxicon</source><volume>56</volume><fpage>1007</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.07.005</pub-id><pub-id pub-id-type="pmid">20638400</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China</article-title><source>Stroke</source><volume>51</volume><fpage>2219</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.030365</pub-id><pub-id pub-id-type="pmid">32466735</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>ML</given-names></name><name><surname>Nuttall</surname><given-names>J</given-names></name><name><surname>Hart</surname><given-names>PA</given-names></name><name><surname>Team</surname><given-names>TI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)</article-title><source>Trials</source><volume>20</volume><elocation-id>501</elocation-id><pub-id pub-id-type="doi">10.1186/s13063-019-3606-y</pub-id><pub-id pub-id-type="pmid">31412955</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathore</surname><given-names>AP</given-names></name><name><surname>Mantri</surname><given-names>CK</given-names></name><name><surname>Aman</surname><given-names>SA</given-names></name><name><surname>Syenina</surname><given-names>A</given-names></name><name><surname>Ooi</surname><given-names>J</given-names></name><name><surname>Jagaraj</surname><given-names>CJ</given-names></name><name><surname>Goh</surname><given-names>CC</given-names></name><name><surname>Tissera</surname><given-names>H</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Gubler</surname><given-names>DJ</given-names></name><name><surname>St John</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dengue virus-elicited tryptase induces endothelial permeability and shock</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>4180</fpage><lpage>4193</lpage><pub-id pub-id-type="doi">10.1172/JCI128426</pub-id><pub-id pub-id-type="pmid">31265436</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Hoffmann</surname><given-names>H-H</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Mendoza</surname><given-names>P</given-names></name><name><surname>Rutkowska</surname><given-names>M</given-names></name><name><surname>Bednarski</surname><given-names>E</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Agudelo</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20201181</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20201181</pub-id><pub-id pub-id-type="pmid">32692348</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>AD</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis</article-title><source>BMJ (Clinical Research Ed.)</source><volume>371</volume><elocation-id>m4750</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m4750</pub-id><pub-id pub-id-type="pmid">33323376</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Lu-Culligan</surname><given-names>A</given-names></name><name><surname>Prado</surname><given-names>AV</given-names></name><name><surname>Skriabine</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Weizman</surname><given-names>O-E</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Szigeti-Buck</surname><given-names>K</given-names></name><name><surname>Yasumoto</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Castaldi</surname><given-names>C</given-names></name><name><surname>Heltke</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>E</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Alfajaro</surname><given-names>MM</given-names></name><name><surname>Levavasseur</surname><given-names>E</given-names></name><name><surname>Fontes</surname><given-names>B</given-names></name><name><surname>Ravindra</surname><given-names>NG</given-names></name><name><surname>Van Dijk</surname><given-names>D</given-names></name><name><surname>Mane</surname><given-names>S</given-names></name><name><surname>Gunel</surname><given-names>M</given-names></name><name><surname>Ring</surname><given-names>A</given-names></name><name><surname>Kazmi</surname><given-names>SAJ</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Wilen</surname><given-names>CB</given-names></name><name><surname>Horvath</surname><given-names>TL</given-names></name><name><surname>Plu</surname><given-names>I</given-names></name><name><surname>Haik</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>J-L</given-names></name><name><surname>Louvi</surname><given-names>A</given-names></name><name><surname>Farhadian</surname><given-names>SF</given-names></name><name><surname>Huttner</surname><given-names>A</given-names></name><name><surname>Seilhean</surname><given-names>D</given-names></name><name><surname>Renier</surname><given-names>N</given-names></name><name><surname>Bilguvar</surname><given-names>K</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neuroinvasion of SARS-CoV-2 in human and mouse brain</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20202135</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20202135</pub-id><pub-id pub-id-type="pmid">33433624</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stangier</surname><given-names>J</given-names></name><name><surname>Clemens</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor</article-title><source>Clinical and Applied Thrombosis/Hemostasis</source><volume>15</volume><fpage>9S</fpage><lpage>16S</lpage><pub-id pub-id-type="doi">10.1177/1076029609343004</pub-id><pub-id pub-id-type="pmid">19696042</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefely</surname><given-names>JA</given-names></name><name><surname>Christensen</surname><given-names>BB</given-names></name><name><surname>Gogakos</surname><given-names>T</given-names></name><name><surname>Cone Sullivan</surname><given-names>JK</given-names></name><name><surname>Montgomery</surname><given-names>GG</given-names></name><name><surname>Barranco</surname><given-names>JP</given-names></name><name><surname>Van Cott</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism</article-title><source>American Journal of Hematology</source><volume>95</volume><fpage>1522</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1002/ajh.25979</pub-id><pub-id pub-id-type="pmid">32833259</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>MR</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0174827</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0174827</pub-id><pub-id pub-id-type="pmid">28358853</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>MR</given-names></name><name><surname>Kinder</surname><given-names>JT</given-names></name><name><surname>Segall</surname><given-names>M</given-names></name><name><surname>Dutch</surname><given-names>RE</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses</article-title><source>Virology</source><volume>543</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2020.01.004</pub-id><pub-id pub-id-type="pmid">32056846</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Matsuno</surname><given-names>S</given-names></name><name><surname>Sunamura</surname><given-names>M</given-names></name><name><surname>Kakugawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis</article-title><source>American Journal of Surgery</source><volume>171</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(97)89617-1</pub-id><pub-id pub-id-type="pmid">8604829</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>Bidon</surname><given-names>MK</given-names></name><name><surname>Straus</surname><given-names>MR</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin</article-title><source>ACS Infectious Diseases</source><volume>7</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00701</pub-id><pub-id pub-id-type="pmid">33432808</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Xue</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Vandana</surname><given-names>JJ</given-names></name><name><surname>Acklin</surname><given-names>JA</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Bram</surname><given-names>Y</given-names></name><name><surname>Chandar</surname><given-names>V</given-names></name><name><surname>Chong</surname><given-names>ACN</given-names></name><name><surname>Lacko</surname><given-names>LA</given-names></name><name><surname>Min</surname><given-names>Z</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Borczuk</surname><given-names>AC</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>SARS-CoV-2 infection induces beta cell transdifferentiation</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>1577</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.05.015</pub-id><pub-id pub-id-type="pmid">34081913</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tormoen</surname><given-names>GW</given-names></name><name><surname>Khader</surname><given-names>A</given-names></name><name><surname>Gruber</surname><given-names>A</given-names></name><name><surname>McCarty</surname><given-names>OJT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor</article-title><source>Physical Biology</source><volume>10</volume><elocation-id>036003</elocation-id><pub-id pub-id-type="doi">10.1088/1478-3975/10/3/036003</pub-id><pub-id pub-id-type="pmid">23585459</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsivgoulis</surname><given-names>G</given-names></name><name><surname>Palaiodimou</surname><given-names>L</given-names></name><name><surname>Zand</surname><given-names>R</given-names></name><name><surname>Lioutas</surname><given-names>VA</given-names></name><name><surname>Krogias</surname><given-names>C</given-names></name><name><surname>Katsanos</surname><given-names>AH</given-names></name><name><surname>Shoamanesh</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>VK</given-names></name><name><surname>Shahjouei</surname><given-names>S</given-names></name><name><surname>Baracchini</surname><given-names>C</given-names></name><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Gournellis</surname><given-names>R</given-names></name><name><surname>Sfikakis</surname><given-names>PP</given-names></name><name><surname>Sandset</surname><given-names>EC</given-names></name><name><surname>Alexandrov</surname><given-names>AV</given-names></name><name><surname>Tsiodras</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 and cerebrovascular diseases: a comprehensive overview</article-title><source>Therapeutic Advances in Neurological Disorders</source><volume>13</volume><elocation-id>1756286420978004</elocation-id><pub-id pub-id-type="doi">10.1177/1756286420978004</pub-id><pub-id pub-id-type="pmid">33343709</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Schaefer-Babajew</surname><given-names>D</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Turroja</surname><given-names>M</given-names></name><name><surname>West</surname><given-names>KA</given-names></name><name><surname>Gordon</surname><given-names>K</given-names></name><name><surname>Millard</surname><given-names>KG</given-names></name><name><surname>Ramos</surname><given-names>V</given-names></name><name><surname>Da Silva</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Colbert</surname><given-names>RA</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Dizon</surname><given-names>J</given-names></name><name><surname>Unson-O’Brien</surname><given-names>C</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Casellas</surname><given-names>R</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title><source>Nature</source><volume>592</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><pub-id pub-id-type="pmid">33567448</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Allen</surname><given-names>JD</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Crispin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><volume>369</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmid">32366695</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>DaSilva</surname><given-names>J</given-names></name><name><surname>Poston</surname><given-names>D</given-names></name><name><surname>Lorenzi</surname><given-names>JC</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Rutkowska</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>H-H</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Agudelo</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Luchsinger</surname><given-names>L</given-names></name><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title><source>eLife</source><volume>9</volume><elocation-id>e61312</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.61312</pub-id><pub-id pub-id-type="pmid">33112236</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>Marks</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1994">1994</year><source>Scientific Foundations of Biochemistry in Clinical Practice</source><publisher-name>Butterworth Heinemann</publisher-name></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>JP</given-names></name><name><surname>Silveira</surname><given-names>JR</given-names></name><name><surname>Maille</surname><given-names>NM</given-names></name><name><surname>Haynes</surname><given-names>LM</given-names></name><name><surname>Tracy</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity</article-title><source>Blood</source><volume>117</volume><fpage>1710</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-09-311035</pub-id><pub-id pub-id-type="pmid">21131592</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrobel</surname><given-names>AG</given-names></name><name><surname>Benton</surname><given-names>DJ</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Roustan</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Rosenthal</surname><given-names>PB</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0468-7</pub-id><pub-id pub-id-type="pmid">32647346</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence for Gastrointestinal Infection of SARS-CoV-2</article-title><source>Gastroenterology</source><volume>158</volume><fpage>1831</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.055</pub-id><pub-id pub-id-type="pmid">32142773</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaghi</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Mac Grory</surname><given-names>B</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name><name><surname>Humbert</surname><given-names>K</given-names></name><name><surname>Henninger</surname><given-names>N</given-names></name><name><surname>Trivedi</surname><given-names>T</given-names></name><name><surname>Lillemoe</surname><given-names>K</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Sanger</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Scher</surname><given-names>E</given-names></name><name><surname>Dehkharghani</surname><given-names>S</given-names></name><name><surname>Wachs</surname><given-names>M</given-names></name><name><surname>Tanweer</surname><given-names>O</given-names></name><name><surname>Volpicelli</surname><given-names>F</given-names></name><name><surname>Bosworth</surname><given-names>B</given-names></name><name><surname>Lord</surname><given-names>A</given-names></name><name><surname>Frontera</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 and Stroke in a New York Healthcare System</article-title><source>Stroke</source><volume>51</volume><fpage>2002</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.030335</pub-id><pub-id pub-id-type="pmid">32432996</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>R</given-names></name><name><surname>Gomez Castro</surname><given-names>MF</given-names></name><name><surname>McCune</surname><given-names>BT</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Sonnek</surname><given-names>NM</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Brulois</surname><given-names>KF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Greenberg</surname><given-names>HB</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Ciorba</surname><given-names>MA</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eabc3582</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abc3582</pub-id><pub-id pub-id-type="pmid">32404436</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Vedantham</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Agudelo</surname><given-names>J</given-names></name><name><surname>Carrion</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Nunneley</surname><given-names>JW</given-names></name><name><surname>Barnard</surname><given-names>D</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name><name><surname>McKerrow</surname><given-names>JH</given-names></name><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title><source>Antiviral Research</source><volume>116</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><pub-id pub-id-type="pmid">25666761</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet (London, England)</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Estes</surname><given-names>SK</given-names></name><name><surname>Ali</surname><given-names>RA</given-names></name><name><surname>Gandhi</surname><given-names>AA</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Sule</surname><given-names>G</given-names></name><name><surname>Gockman</surname><given-names>K</given-names></name><name><surname>Madison</surname><given-names>JA</given-names></name><name><surname>Zuo</surname><given-names>M</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Woodard</surname><given-names>W</given-names></name><name><surname>Lezak</surname><given-names>SP</given-names></name><name><surname>Lugogo</surname><given-names>NL</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Morrissey</surname><given-names>JH</given-names></name><name><surname>Kanthi</surname><given-names>Y</given-names></name><name><surname>Knight</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eabd3876</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abd3876</pub-id><pub-id pub-id-type="pmid">33139519</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77444.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><p>This study examines the potential role host proteases involved in coagulation may play in proteolytic processing of the SARS CoV-2 virus spike protein, which is required for viral entry. Serine protease inhibitors such as nafamostat and camostat may limit viral entry into host cells and also be useful to treat coagulopathy in patients with SARS CoV-2 infection, particularly if treatment is initiated early.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77444.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77444.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Evidence, reproducibility and clarity (Required)):</p><p>This paper shows that cleavage of SARS-CoV-2 spike protein is necessary for infection and that this is mediated by host proteases. Specifically, they show that activated coagulation factors are effective at cleaving spike protein.</p><p>Major comments</p><p>The authors clearly show that coagulation factors, especially FXa and thrombin, are capable of cleaving spike protein, as is TMPRSS2. They also show that the protease inhibitor nafamostat is effective at inhibiting spike protein cleavage.</p></disp-quote><p>We appreciate the Reviewer’s positive comments about our manuscript and we are grateful that the Reviewer concurs that our conclusions are clearly shown by the experimental data.</p><disp-quote content-type="editor-comment"><p>The evidence for a role for coagulation proteins in vivo is weak. Despite the use of anti-coagulants as standard of care the evidence for their benefit is weak and even studies using higher doses have not been very promising. This suggests that TMPRSS2 is the important enzyme and as long as it is uninhibited spike protein cleavage will still occur.</p></disp-quote><p>The Reviewer rightly points out the inherent challenge of reconciling clinical observation, which suffer from limited control over important variables and lack of molecular detail, with controlled perturbation experiments, which require compromises in approximating the physiological setting. We made our best effort to be precise in the text to not overextend our claims beyond what can be supported by the data and, where appropriate, to cite the copious but circumstantial clinical evidence that supports the physiological relevance of dysregulated coagulation in COVID-19.</p><p>A safe and effective drug regimen to address COVID-19 coagulopathy has not been optimized and is urgently needed. As the reviewer points out, multiple clinical trials failed to detect a reduction in organ support-free days following therapeutic dose over prophylactic dose heparin (A. Investigators et al., 2021; R.-C. Investigators et al., 2021). Timing is a critical factor in the interpretation of the potential for direct antiviral effects of anti-coagulation strategies. In the aforementioned studies, treatment occurred in-hospital, typically during the inflammatory phase of disease, after the peak of viral titer has already passed (Griffin et al., 2021). Thus, any antiviral effect of DOACs, for instance, are difficult to evaluate in this context. We observed that apixaban reverses the effect of exogenous FXa, but its overall effect was partial, presumably since it spares the activity of both furin and TMPRSS2 (Supplementary Figure 9). For this reason, we would predict that heparin or commonly used DOACs might have a modest antiviral effect if applied soon after disease onset, but that other drugs with a dual mechanism towards coagulation proteases and TMPRSS2/TTSPs, would be a far superior strategy.</p><p>Our results demonstrate that factor Xa can activate SARS-CoV-2 spike in cells with or without TMPRSS2 expression (Figure 3G) and that dual inhibition of factor Xa and TMPRSS2 with nafamostat can have a remarkable effect on spike-mediated entry (Figure 4 G-H, Supplementary Figure 9) without impacting furin (Supplementary Figure 8A). Our interpretation is that TMPRSS2 is one important host protease in the process of SARS-CoV-2 infection, but is unlikely to be the only important host protease. It remains challenging to fully reproduce the complex biological process of coagulation in cell culture and therefore care must be taken when extrapolating in vitro results to the human condition. Experiments with psuedoparticles and enzymatic assays using peptide substrates allow for precisely controlled conditions and provide mechanistic insight for the involvement of coagulation factors in SARS-CoV-2 spike-mediated entry.</p><p>During the course of revision, we added an additional experiment that we believe has strong physiological relevance. We generated lung organoids by stepwise differentiation of human pluripotent stem cells, which recapitulates more of the form and function of human lung tissues than lung-derived cell lines grown in standard culture conditions. We used this material to conduct an infection experiment with WT SARS-CoV-2 in lung organoids to achieve greater physiological relevance. For details, please refer to Methods (lines 664-710). We describe this experiment in the main text as follows (lines 261-277):</p><p>“Factor Xa and thrombin increase SARS-CoV-2 infection in lung organoids</p><p>To explore the effect of coagulation factors in a more physiologically relevant setting, we exposed human pluripotent stem cell-derived lung organoids (hPSC-LOs) to SARS-CoV-2 infection under BSL-3 conditions with or without addition of exogenous protease. […] This effect was accentuated at 48 hours post infection with respect to 24 hours post infection, and with lower initiating MOI. Factor Xa and thrombin increase SARS-CoV-2 infection in the context of multicycle viral replication in human lung organoids.”</p><disp-quote content-type="editor-comment"><p>Furthermore, there is significant evidence to show that coagulopathy associated with COVID-19 and other severe viral infections is in fact platelet driven (Cox D. Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis. Frontiers in Pharmacology. 2021;12). An interesting fact about nafamostat and the related protease inhibitor pentamidine is that they are both GPIIb/IIIa antagonists (Cox D, Aoki T, Seki J, Motoyama Y and Yoshida K. Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost. 1996;75:503-9). SARS-CoV-2 spike protein has an RGD sequence possibly allowing it to bind to platelet GPIIb/IIIa. Thus, nafamostat has three potential benefits in COVID-19: inhibition of spike protein cleavage, inhibition of SARS-CoV-2 binding to platelet GPIIb/IIIa and inhibition of platelet aggregation and thus thrombus formation.</p></disp-quote><p>We appreciate the Reviewer’s comments. We will incorporate the points raised and the references mentioned above into the discussion (lines 328-331 and 356-358), concerning the model of a platelet-driven COVID-19 coagulopathy and how this relates to an additional potential mechanism of nafamostat, respectively.</p><p>Line 328-331:</p><p>“Furthermore, one model posits that COVID-19 coagulopathy is platelet-driven and an Arg-Gly-Asp (RGD) motif on SARS-CoV-2 spike directly interacts with GPIIb/GPIIIa integrins on the surface of platelets (Cox, 2021), consistent with in silico predictions of integrin binding (Meszaros et al., 2021).”</p><p>Line 356-358:</p><p>“It is also plausible that nafamostat, like related protease inhibitor pentamidine, could also interfere with platelet GPIIb/IIIa, platelet aggregation and thrombus formation (Cox, 2021; Cox et al., 1996).”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance (Required)):</p><p>This is an interesting insight into the role of proteases in SARS-CoV-2 and may be a potential therapeutic strategy in COVID-19.</p><p>I am a pharmacologist so my expertise is not in biochemistry but have a major interest in viral-mediated thrombosis.</p></disp-quote><p>We thank the Reviewer for their time, consideration, and expertise. We hope that readers will also be interested in the potential role of coagulation proteases in SARS-CoV-2 and how this reframes the approach to protease inhibitors currently under clinical investigation.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Evidence, reproducibility and clarity (Required)):</p><p>The authors present a study exploring the potential that host proteases involved in coagulation play a role in proteolytic processing of the spike protein on the SARS CoV-2 virus required for viral entry into target cells. They propose broad based serine protease inhibitors such as nafamostat and camostat could be useful in limiting viral entry into host cells as well as reducing coagulopathy related problems in patients with SARS CoV-2 infection particularly if treatment is initiated early in the disease course. The authors use FRET based enzymatic assays in purified systems to demonstrate that peptides mimicking the S1/S2 and S2'cleavage sites of the SARS CoV-2 spike protein can be cleaved by coagulation proteases FXa and thrombin at rates comparable to that of TMPRSS2. TMPRSS2 has been established in the relevant literature to be an important host protease involved in the proteolytic activation of several coronaviruses. In addition, the authors present data from cell based pseudoviral infection assays to demonstrate the ability of coagulation proteases to process the particles for cell entry as well as the effectiveness of inhibitors such as nafamostat and camostat in preventing infection by SARS CoV-2 pseudovirons.</p><p>The data presented provides convincing support for the conclusions reached by the authors. Suitable control experiments using modified FRET peptides with key residues altered to make them poorer substrates for FXa and thrombin provided additional weight to support the conclusion that coagulation proteases could play a role in processing the spike protein for viral entry.</p></disp-quote><p>We appreciate the reviewer’s positive comments about our manuscript and we are grateful that the reviewer concurs that our conclusions are convincingly supported by the experimental data and that appropriate controls were included.</p><disp-quote content-type="editor-comment"><p>Prior studies seem to be referenced appropriately. The text and figures are clear and accurate.</p></disp-quote><p>We thank the reviewer for remarking on the appropriate contextualization of other studies in the field and the accuracy and clarity of the text and figures.</p><disp-quote content-type="editor-comment"><p>The authors may consider including phospholipids in the assay where they measure activity of FXa toward its &quot;known&quot; substrate THRBR271 to reduce the potential for overstating the preference for the S1/S2 peptide over natural FXa substrates.</p></disp-quote><p>We thank the Reviewer for raising this point. We agree with that the results of factor Xa enzymatic assays are dependent on assay-specific conditions including pH and buffer composition. We aimed to clarify our statement on FXa substrate selectivity to reflect the reviewer’s suggestion (lines 163-165, 178-180):</p><p>Line 163-165:</p><p>“factor Xa showed ~9-fold greater maximum initial reaction velocity (Vmax) in cleaving the spike S1/S2 peptide compared to cleaving a peptide corresponding to its known substrate, THRB<sup>R271</sup>”</p><p>Line 178-180:</p><p>“In summary, the coagulation serine proteases factor Xa and thrombin exhibit proteolytic activity against SARS-CoV-2 peptide substrates.”</p><p>Furthermore, we conducted the factor Xa enzymatic assays with the addition of phosphatidylcholine/phosphatidylserine (PC/PS) to determine the effect on factor Xa substrate preference. The results were added to Supplementary Figure 5 (related to figure 2). We found that the addition of phospholipid vesicles did not change factor Xa activity or substrate preference in this assay (Figure S5E). To ensure the quality of our phospholipid vesicle preparation, we added 0-100 µM PC/PS to a dilute Russell’s Viper Venom time clotting assay, where PC/PS drives a significant, concentration-dependent acceleration of clotting of normal pooled human plasma (Figure S5E). The dRVVT test was selected over more common coagulation assays because it relies on direct activation of factor X to Xa and does not rely on reagents that include exogenous phospholipids.</p><p>Our interpretation is that the use of purified, RVV-activated factor Xa and peptide substrates in the enzymatic assay renders the reaction independent of phospholipid membranes. On the surface of platelets, one might expect that providing a membrane scaffold, thereby spatially restricting the tenase complex that activates factor Xa, could potentially increase the velocity of the cleavage activation of factor X, by increasing the likelihood of collision of fX and tenase (Basavaraj and Krishnaswamy, 2020; Husten, Esmon, and Johnson, 1987). However, our assay relies on purified factor Xa, activated by Russell’s viper venom (Tans and Rosing, 2001), alleviating the requirement for upstream activation. The use of peptide substrates in this assay has the consequence that downstream cleavage requires that enzyme and substrate meet in 3-dimensional space, rather than along the surface of a 2-dimensional membrane.</p><p>Lines 590-600 (Methods):</p><p>“Phospholipid vesicles</p><p>Phosphatidylcholine (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids #850375C) and phosphatidylserine (1,2-dioleoyl-sn-glycero-3-phospho-L-serine, Avanti Polar Lipids #840035C) were mixed in a 3:1 w/w ratio in chloroform solvent in a screw top vial and the chloroform solvent was evaporated under a nitrogen stream. Unilamellar vesicles were isolated by extrusion using 0.1 micron pore filters and diluted in buffer AB2 (50mM Tris-HCl, 150mM NaCl, pH 8). The addition of phospholipid vesicles did not change factor Xa activity or substrate preference in this assay (Figure S5E). To ensure the quality of our phospholipid vesicle preparation, we added 0-100 µM PC/PS to a dilute Russell’s Viper Venom time clotting assay, where PC/PS drives a significant, concentration-dependent acceleration of clotting of normal pooled human plasma (Figure S5E).”</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Significance (Required)):</p><p>Given the rapidly evolving nature of the SARS CoV-2 pandemic the work presented in the manuscript should be relevant to both the fields of virology and coagulation. The potential for treatments aimed at inhibiting both TMPRSS2 and coagulation associated proteases should be of interest to both clinicians and basic science researchers involved in the treatment and research of SARS CoV-2.</p></disp-quote><p>We appreciate that the Reviewer found the manuscript to be relevant and of broad interest to the fields of virology and coagulation. We also hope that the work is of interest to both clinicians and basic scientists.</p><p>References:</p><p>Basavaraj, M. G., and Krishnaswamy, S. (2020). Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex. <italic>J Biol Chem, 295</italic>(45), 15198-15207. doi:10.1074/jbc.RA120.015325</p><p>Cox, D. (2021). Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis. <italic>Front Pharmacol, 12</italic>, 708665. doi:10.3389/fphar.2021.708665</p><p>Cox, D., Aoki, T., Seki, J., Motoyama, Y., and Yoshida, K. (1996). Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. <italic>Thromb Haemost, 75</italic>(3), 503-509. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8701416</p><p>Griffin, D. O., Brennan-Rieder, D., Ngo, B., Kory, P., Confalonieri, M., Shapiro, L.,... Marik, P. (2021). The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <italic>AIDS Rev</italic>. doi:10.24875/AIDSRev.200001261</p><p>Husten, E. J., Esmon, C. T., and Johnson, A. E. (1987). The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. <italic>J Biol Chem, 262</italic>(27), 12953-12961. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/3477541</p><p>Investigators, A., Investigators, A. C.-a., Investigators, R.-C., Lawler, P. R., Goligher, E. C., Berger, J. S.,... Zarychanski, R. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <italic>N Engl J Med, 385</italic>(9), 790-802. doi:10.1056/NEJMoa2105911</p><p>Investigators, R.-C., Investigators, A. C.-a., Investigators, A., Goligher, E. C., Bradbury, C. A., McVerry, B. J.,... Zarychanski, R. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <italic>N Engl J Med, 385</italic>(9), 777-789. doi:10.1056/NEJMoa2103417</p><p>Meszaros, B., Samano-Sanchez, H., Alvarado-Valverde, J., Calyseva, J., Martinez-Perez, E., Alves, R.,... Gibson, T. J. (2021). Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. <italic>Sci Signal, 14</italic>(665). doi:10.1126/scisignal.abd0334</p><p>Tans, G., and Rosing, J. (2001). Snake venom activators of factor X: an overview. <italic>Haemostasis, 31</italic>(3-6), 225-233. doi:10.1159/000048067</p></body></sub-article></article>